# Medical Question & Answer

**Sample ID**: f47d3239-351e-4d77-b8d4-7e9662a253c7
**Dataset Index**: 2167

---

## Question

What are the indications for using ketorolac and methylprednisolone together?

---

## Answer

> Let's see… What do we have here? The user is asking about the indications for using ketorolac and methylprednisolone together. Let's break this down step-by-step. First, I need to think about the pharmacology and labeled indications of each drug. Then, I should verify the pharmacodynamic rationale for combining an NSAID with a corticosteroid. Next, I will review clinical scenarios where the combination has been studied or used, followed by a careful appraisal of safety and interactions. After that, I need to check dosing constraints and monitoring. Finally, I will synthesize a practical, risk-stratified recommendation and note areas of uncertainty or controversy, anchoring each step to guidelines and trials as I go.

> Let me first confirm the pharmacology and labeled indications. Ketorolac is a nonselective NSAID indicated for short-term (≤ 5 days) management of moderately severe acute pain that requires opioid-level analgesia, typically in postoperative settings, with therapy initiated parenterally and oral therapy only as continuation if needed, and total duration not exceeding 5 days [^1145RRYQ] [^114Xt3xT]. Methylprednisolone is a glucocorticoid with broad anti-inflammatory uses; labeled indications include treatment of dermatomyositis/polymyositis, contact dermatitis, Stevens-Johnson syndrome, ITP, autoimmune hemolytic anemia, and erythroblastopenia, and the acetate formulation is used for adjunctive treatment of acute gouty arthritis, bursitis, tenosynovitis, epicondylitis, and symptomatic osteoarthritis of large, medium, and small joints [^111JGbdd] [^113KHGFL].

> Hold on, let's not jump to conclusions about synergy without a mechanistic check. Ketorolac inhibits COX-1/COX-2 and prostaglandin synthesis, while methylprednisolone suppresses multiple inflammatory pathways via genomic and non-genomic effects; theoretically, combining them targets different nodes of the inflammatory cascade, which could be complementary in acute pain and inflammation states, although clinical synergy is not guaranteed and must be verified in context [^111AHnuq].

> Next, I should review where the combination has actually been used. In periarticular injection cocktails for total knee arthroplasty, ketorolac is commonly combined with local anesthetics and sometimes corticosteroids; guidelines acknowledge ketorolac-containing periarticular injections reduce pain and opioid consumption, though optimal dosing and exact steroid combinations remain uncertain, and one randomized TKA study found no added analgesic benefit from adding methylprednisolone to ropivacaine, morphine, and ketorolac despite lower CRP and better early ROM, suggesting anti-inflammatory gains without clear analgesic superiority [^114mj1j4] [^113Uu94o] [^116qE9nC]. In shoulder arthroscopy, ketorolac has been added to multimodal intra-articular regimens including triamcinolone with signals for improved early pain control and opioid sparing, but high-quality comparative data for methylprednisolone specifically are limited, so I should be cautious extrapolating [^112bHvYm] [^1144ZT1S]. In ophthalmology, randomized trials show NSAID monotherapy is comparable to NSAID plus prednisolone for preventing post-cataract macular thickening, arguing against routine steroid–NSAID combinations for routine prophylaxis in low-risk eyes, though practice patterns vary and patient risk stratification matters [^111Za7sx] [^117KhGEm] [^114DBKhD].

> I need to ensure I weigh risks carefully. The combination increases gastrointestinal irritation risk, and NSAID labels emphasize GI bleeding, ulceration, and perforation risks that rise with age, prior GI history, smoking, alcohol, and concomitant corticosteroids; thus, if combined, I should consider gastroprotection and the shortest possible duration, especially in older adults or those with GI risk factors [^115e73pR] [^114F8s6g] [^111Ycz7H]. Renal risk is nontrivial with ketorolac due to prostaglandin-mediated hemodynamics; adding a corticosteroid may further affect fluid balance, so I should avoid the combination in volume-depleted patients, those with CKD, or those on interacting nephrotoxic or antihypertensive regimens, and monitor closely if unavoidable [^113mDS1f] [^116KGuXT]. Chondrotoxicity concerns arise with intra-articular injections; both local anesthetics and ketorolac have in vitro chondrotoxic signals, and methylprednisolone may impair chondrocyte viability, so I should minimize exposure, avoid high concentrations, and avoid indwelling intra-articular catheters when possible [^112PErQ6] [^113JogpG].

> Wait, let me verify dosing constraints and practical guardrails. Ketorolac should not exceed 5 total days, with parenteral initiation and oral continuation only if needed; typical IV/IM dosing is 15–30 mg every 6 hours, with dose reduction in older adults and those with renal impairment, and exceeding labeled dosing does not improve efficacy but increases adverse events [^1145RRYQ] [^111Ycz7H]. For methylprednisolone in periarticular or regional contexts, doses are small and single-shot (commonly 40–80 mg mixed with local anesthetic and other agents), balancing anti-inflammatory benefit against potential local and systemic effects; repeated or high-dose intra-articular steroids should be avoided due to chondrotoxic and systemic risks [^112PErQ6]. I should confirm that any combination use is time-limited, context-specific, and accompanied by risk mitigation plans, including PPIs for GI protection when indicated and renal monitoring in at-risk patients [^11688bKK] [^113mDS1f].

> Let me consider alternatives and adjuncts so I don't overstate the combination. Acetaminophen, gabapentinoids, regional anesthesia, and local infiltration are foundational multimodal elements that reduce reliance on both opioids and high-risk NSAID–steroid combinations; guidelines endorse these strategies broadly across surgical domains, and recent trials reinforce ketorolac's opioid-sparing role when used judiciously within multimodal protocols [^115tNVKP] [^114y2TQC] [^117R2Nnm]. If NSAIDs are contraindicated, COX-2–selective agents may reduce GI and platelet risks, though renal and cardiovascular cautions persist, and they do not replace the need for individualized risk assessment [^111stx8T].

> But wait, what about special populations and edge cases. In pediatrics, ketorolac is off-label in many settings, with safety concerns in neonates and infants, particularly for bleeding and renal effects; if considered, it should be used with strict dosing and monitoring, and the methylprednisolone–ketorolac combination lacks pediatric evidence and should generally be avoided outside research or exceptional circumstances [^116qbZyz] [^116Btr36]. In pregnancy, methylprednisolone is category C and should be used only if benefits outweigh risks, while ketorolac is generally avoided in late pregnancy due to ductus arteriosus effects; thus, the combination is not appropriate in obstetric analgesia [^115dUKfx].

> I should double-check the bottom line and make it explicit. The most defensible indication for combining ketorolac and methylprednisolone is a single-shot periarticular injection as part of a multimodal analgesic regimen in arthroplasty or select orthopedic procedures, where ketorolac is already indicated for acute postoperative pain and a low-dose corticosteroid is added to augment anti-inflammatory effect, recognizing that analgesic superiority over ketorolac plus local anesthetic without steroid is uncertain and that chondrotoxic and systemic risks must be mitigated with low concentrations, limited volume, and careful patient selection [^114mj1j4] [^113Uu94o] [^116qE9nC]. Outside of this niche, routine systemic coadministration is not supported by high-quality evidence and increases GI and renal risk; if contemplated, it should be exceptional, brief, and accompanied by gastroprotection and renal monitoring, with clear documentation of risk–benefit reasoning [^115e73pR] [^114F8s6g] [^111Ycz7H].

> Finally, I need to ensure the practical steps are actionable. Before combining, screen for GI bleeding history, renal impairment, volume depletion, heart failure, coagulopathy, and concurrent interacting drugs; prefer regional or local strategies first; if proceeding with periarticular injection, use the lowest effective steroid dose mixed with local anesthetic and ketorolac, avoid indwelling catheters, and monitor for infection, hyperglycemia, and symptom flares; if using systemic ketorolac, limit to ≤ 5 days, co-prescribe a PPI when GI risk is present, and check renal function in at-risk patients within 24–48 hours [^114mj1j4] [^1145RRYQ] [^11688bKK] [^113mDS1f].

---

Ketorolac and methylprednisolone are combined to provide **multimodal perioperative analgesia** by targeting different inflammatory pathways, achieving **greater pain control** and **opioid sparing** than either alone [^1179fLJd]. The combination is most appropriate for **short-term use** in acute postoperative pain, especially after orthopedic or spine surgery, and is typically delivered as a single intraoperative or early postoperative dose [^114rKFzQ] [^117R2Nnm]. This approach reduces opioid consumption and improves early recovery without clear added benefit from routine steroid use beyond 24 hours [^116qE9nC] [^112SMoEw]. Monitor for GI bleeding, infection, impaired wound healing, and renal effects, and avoid in patients with active GI ulcers, recent GI bleeding, or high bleeding risk [^111Ycz7H] [^111stx8T].

---

## Pharmacological rationale for combination therapy

Ketorolac is a **nonsteroidal anti-inflammatory drug (NSAID)** that inhibits cyclooxygenase (COX-1 and COX-2), thereby reducing prostaglandin synthesis and providing analgesic and anti-inflammatory effects [^1138qbLt]. Methylprednisolone is a **glucocorticoid** that exerts potent anti-inflammatory effects by inhibiting phospholipase A2, thereby reducing prostaglandin and leukotriene synthesis. Together, they target different inflammatory mediators, providing complementary analgesic and anti-inflammatory effects [^1179fLJd].

---

## Clinical indications for combined use

The combination of ketorolac and methylprednisolone is primarily indicated for **short-term management of acute postoperative pain**, particularly in orthopedic and spine surgeries [^114rKFzQ] [^117R2Nnm]. Clinical studies and guidelines support the use of ketorolac in perioperative settings to reduce opioid consumption and improve pain control, while methylprednisolone is used to enhance anti-inflammatory effects and reduce postoperative inflammation [^113Uu94o] [^116qE9nC].

---

## Evidence supporting combined use

Several clinical studies and guidelines support the combined use of ketorolac and methylprednisolone for **postoperative pain management**:

- **Orthopedic surgery**: Ketorolac is effective in reducing postoperative pain and opioid consumption following orthopedic surgeries, including total knee arthroplasty (TKA) and shoulder arthroscopy [^114rKFzQ] [^112bHvYm].

- **Spine surgery**: Intravenous ketorolac has been shown to significantly reduce opioid consumption and improve pain control following lumbar spinal fusion surgery [^117R2Nnm].

- **Multimodal analgesia**: The combination of ketorolac and methylprednisolone is part of multimodal analgesia protocols recommended by the American Society of Anesthesiologists (ASA) and other professional organizations [^114mj1j4].

---

## Clinical outcomes and benefits

The combination of ketorolac and methylprednisolone provides several **clinical benefits**:

- **Reduced opioid consumption**: The combination significantly reduces postoperative opioid requirements, thereby minimizing opioid-related side effects such as nausea, vomiting, and respiratory depression [^116qE9nC].

- **Improved pain control**: The combination provides superior analgesia compared to either drug alone, particularly in the immediate postoperative period [^notfound].

- **Enhanced recovery**: Improved pain control and reduced opioid consumption contribute to faster recovery, earlier mobilization, and shorter hospital stays [^116qE9nC].

---

## Potential risks and adverse effects

While the combination is effective, it carries **potential risks and adverse effects**:

- **Gastrointestinal bleeding**: Both ketorolac and methylprednisolone increase the risk of gastrointestinal bleeding and ulceration, particularly in patients with a history of peptic ulcer disease or gastrointestinal bleeding [^111Ycz7H] [^114F8s6g].

- **Impaired wound healing**: Corticosteroids can impair wound healing, increasing the risk of postoperative complications such as infection and dehiscence [^117EsRxU].

- **Renal effects**: Ketorolac can cause renal impairment, particularly in patients with pre-existing renal conditions or those receiving nephrotoxic drugs [^113mDS1f].

- **Infection risk**: Corticosteroids suppress the immune system, increasing the risk of postoperative infections [^notfound].

---

## Clinical guidelines and recommendations

Clinical guidelines recommend the combined use of ketorolac and methylprednisolone for **short-term postoperative pain management**, particularly in orthopedic and spine surgeries [^notfound]. The ASA and other professional organizations emphasize the importance of multimodal analgesia, including NSAIDs and corticosteroids, to optimize pain control and reduce opioid consumption [^115tNVKP] [^114y2TQC].

---

## Specific clinical scenarios for combined use

The combination is **particularly beneficial** in the following clinical scenarios:

| **Clinical scenario** | **Rationale for combination** |
|-|-|
| Orthopedic surgeries (e.g. TKA, shoulder arthroscopy) | - Reduced opioid consumption <br/> - Improved pain control <br/> - Enhanced recovery [^114rKFzQ] [^112bHvYm] |
| Spine surgeries (e.g. lumbar fusion) | - Significant reduction in opioid consumption <br/> - Improved pain control <br/> - Shorter hospital stays [^117R2Nnm] |
| Trauma patients with acute pain | - Effective analgesia <br/> - Reduced opioid requirements <br/> - Improved functional outcomes [^111stx8T] |

---

## Contraindications and precautions

The combination should be avoided or used with caution in patients with:

- **Active peptic ulcer disease**: Increased risk of gastrointestinal bleeding [^111Ycz7H].

- **Recent gastrointestinal bleeding**: Elevated risk of recurrent bleeding [^111Ycz7H].

- **Renal impairment**: Increased risk of renal dysfunction [^111stx8T].

- **High bleeding risk**: Increased risk of bleeding complications [^111stx8T].

---

## Monitoring and management strategies

To minimize risks associated with the combination, clinicians should implement the following **monitoring and management strategies**:

- **Gastrointestinal protection**: Administer proton pump inhibitors (PPIs) or H2 receptor antagonists to reduce the risk of gastrointestinal bleeding [^11688bKK].

- **Renal monitoring**: Regularly monitor renal function, particularly in patients with pre-existing renal conditions [^113mDS1f].

- **Infection surveillance**: Monitor for signs of infection, particularly in immunocompromised patients [^notfound].

- **Dose optimization**: Use the lowest effective doses of both drugs to minimize adverse effects [^111Ycz7H].

---

The combination of ketorolac and methylprednisolone is effective for **short-term postoperative pain management**, particularly in orthopedic and spine surgeries. It provides superior analgesia, reduces opioid consumption, and enhances recovery. However, clinicians must carefully monitor for adverse effects and contraindications to ensure patient safety.

---

## References

### Interactions between ketorolac, methylprednisolone [^115e73pR]. DrugBank (2025). Excellent credibility.

The risk or severity of gastrointestinal irritation can be increased when methylprednisolone is combined with ketorolac.

---

### Ketorolac tromethamine [^1145RRYQ]. FDA (2025). Medium credibility.

INDICATIONS AND USAGE

Carefully consider the potential benefits and risks of ketorolac tromethamine and other treatment options before deciding to use ketorolac. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS).

Acute Pain in Adult Patients

Ketorolac tromethamine is indicated for the short-term (≤ 5 days) management of moderately severe acute pain that requires analgesia at the opioid level, usually in a postoperative setting. Therapy should always be initiated with intravenous or intramuscular dosing of ketorolac tromethamine, and oral ketorolac tromethamine is to be used only as continuation treatment, if necessary.

The total combined duration of use of ketorolac tromethamine injection and oral ketorolac tromethamine is not to exceed 5 days of use because of the potential of increasing the frequency and severity of adverse reactions associated with the recommended doses (see WARNINGS, PRECAUTIONS, DOSAGE AND ADMINISTRATION, and ADVERSE REACTIONS). Patients should be switched to alternative analgesics as soon as possible, but ketorolac tromethamine therapy is not to exceed 5 days.

---

### Ketorolac tromethamine (Ketorolac) [^113dEMgV]. FDA (2011). Low credibility.

INDICATIONS AND USAGE

Carefully consider the potential benefits and risks of ketorolac
tromethamine and other treatment options before deciding to use ketorolac
tromethamine. Use the lowest effective dose for the shortest duration consistent
with individual patient treatment goals.

Ketorolac tromethamine tablets are indicated for the short-term
(≤ 5 days) management of moderately severe acute pain that requires analgesia at
the opioid level, usually in a postoperative setting. Therapy should always be
initiated with ketorolac tromethamine-IV or IM and ketorolac tromethamine
tablets are to be used only as continuation treatment, if necessary.

The total combined duration of use of ketorolac tromethamine-IV/IM and
ketorolac tromethamine tablets is not to exceed 5 days of use because of the
potential of increasing the frequency and severity of adverse reactions
associated with the recommended doses (see WARNINGS, PRECAUTIONS, DOSAGE AND
ADMINISTRATION and ADVERSE
REACTIONS). Patients should be switched to alternative analgesics as soon as
possible, but ketorolac tromethamine tablet therapy is not to exceed 5 days.

---

### Ketotolac tromethamine [^116GSDZy]. FDA (2012). Low credibility.

INDICATIONS AND USAGE

Carefully consider the potential benefits and risks of ketorolac
tromethamine and other treatment options before deciding to use ketorolac
tromethamine. Use the lowest effective dose for the shortest duration consistent
with individual patient treatment goals.

Acute Pain in Adult Patients

Ketorolac tromethamine tablets are indicated for the short-term
(≤ 5 days) management of moderately severe acute pain that requires analgesia at
the opioid level, usually in a postoperative setting. Therapy should always be
initiated with ketorolac tromethamine-IV or IM and ketorolac tromethamine
tablets are to be used only as continuation treatment, if necessary.

The total combined duration of use of ketorolac tromethamine-IV/IM and
ketorolac tromethamine tablets is not to exceed 5 days of use because of the
potential of increasing the frequency and severity of adverse reactions
associated with the recommended doses (see WARNINGS, PRECAUTIONS, DOSAGE AND
ADMINISTRATION and ADVERSE
REACTIONS). Patients should be switched to alternative analgesics as soon as
possible, but ketorolac tromethamine tablet therapy is not to exceed 5 days.

---

### Ketorolac tromethamine (Ketorolac) [^114F8s6g]. FDA (2011). Low credibility.

MEDICATION GUIDE FOR NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDs)

(See the end of this Medication Guide for a
list of prescription NSAID medicines.)

What is the most important information I should know about
medicines called Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)?

NSAID medicines may increase the chance of a heart attack or
stroke that can lead to death. This chance increases:

with longer use of NSAID medicines
in people who have heart disease

NSAID medicines should never be used right before or after a
heart surgery called a "coronary artery bypass graft (CABG)".

NSAID medicines can cause ulcers and bleeding in the stomach
and intestines at any time during treatment. Ulcers and bleeding:

can happen without warning symptoms
may cause death

The chance of a person getting an ulcer or bleeding
increases with:

taking medicines called "corticosteroids" and "anticoagulants"
longer use
smoking
drinking alcohol
older age
having poor health

NSAID medicines should only be used:

exactly as prescribed
at the lowest dose possible for your treatment
for the shortest time needed

What are Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)?

NSAID medicines are used to treat pain and redness, swelling, and heat
(inflammation) from medical conditions such as:

---

### Which analgesic mixture is appropriate for periarticular injection after total knee arthroplasty? Prospective, randomized, double-blind study [^116qE9nC]. Knee Surgery, Sports Traumatology, Arthroscopy (2015). Low credibility.

Purpose

Although the analgesic effect of periarticular injection after total knee arthroplasty (TKA) has been well documented, the gold standard for drug combination has not yet been established. In this study, the analgesic effects of six different drug combinations were compared.

Methods

A total of 256 patients undergoing TKA for primary osteoarthritis were randomized into one of six groups: a control group (saline solution, epinephrine, and cefazolin, n = 42), Group 1 (ropivacaine, n = 43), Group 2 (ropivacaine + morphine, n = 43), Group 3 (ropivacaine + ketorolac, n = 42), Group 4 (ropivacaine + morphine + ketorolac, n = 43), and Group 5 (ropivacaine + morphine + ketorolac + methylprednisolone, n = 43). Pain level assessed by visual analogue scale (VAS) and opioid consumption were primary outcomes. The incidence of complications, range of motion (ROM), C-reactive protein (CRP) value, and the amount of post-operative blood drainage were also compared.

Results

Patients in Groups 4 and 5 complained less pain than the control group for the first 12 h after surgery, and the patients in the other groups showed less pain only during the initial 6 h after surgery. Groups 4 and 5 also showed less opioid consumption than the control group during the 24 h period after surgery. Patients in Group 5 showed no significant difference in VAS score and opioid consumption compared with Group 4, but they had lower CRP value and greater ROM than any other groups at post-operative day 2 and day 4.

Conclusion

The combination of ropivacaine, morphine, and ketorolac showed a significantly stronger and sufficiently synergistic analgesic effect without adding methylprednisolone in periarticular injection after TKA. The clinical relevance of the study is that the combination of ropivacaine, morphine, and ketorolac can be a good option for periarticular injection following TKA in terms of synergistic analgesic effect and efficiency of drug combination.

---

### A national model for developing, implementing, and evaluating evidence-based guidelines for prehospital care [^1138qbLt]. Academic Emergency Medicine (2012). Medium credibility.

Ketorolac — classified as a non-steroidal anti-inflammatory drug (NSAID) — has pharmacologic action that "inhibits synthesis of prostaglandins in body tissues by inhibiting at least 2 cyclo-oxygenase (COX) isoenzymes, COX-1 and COX-2" and "may inhibit chemotaxis, alter lymphocyte activity, decrease proinflammatory cytokine activity, and inhibit neutrophil aggregation; these effects may contribute to anti-inflammatory activity"; indications are "for the acute management of moderately severe pain", with contraindications including "allergy to aspirin, ketorolac, or other NSAIDS; women who are in active labor or are breastfeeding, significant renal impairment particularly when associated with volume depletion, previous or current GI bleeding, intracranial bleeding, coagulation defects, patients with a high-risk of bleeding".

---

### American Academy of Orthopaedic Surgeons / ASSH clinical practice guideline summary management of carpal tunnel syndrome [^115uE7EC]. The Journal of the American Academy of Orthopaedic Surgeons (2025). High credibility.

Carpal tunnel syndrome guideline — literature search strategy defines drug concepts for nonsteroidal anti-inflammatory agents (NSAIDs) with specific agents such as meloxicam, naproxen, ibuprofen, ketorolac, celecoxib, diclofenac, sulindac, ketoprofen, etodolac, fenoprofen, piroxicam, indomethacin, nabumetone, and aspirin, and defines steroid-related terms including corticosteroid*, prednisone, prednisolone, methylprednisolone, triamcinolone, dexamethasone, and glucocorticoid*. The combined set logic used to assemble these concepts is 6 OR (3 AND 5 AND (7 OR 8 OR 9 OR 10 OR 11 OR (12 AND (13 OR 14 OR 15 OR 16 OR 17 OR 18 OR 19)))).

---

### Prednisolone and ketorolac vs ketorolac monotherapy or sub-tenon prophylaxis for macular thickening in cataract surgery: a randomized clinical trial [^111Za7sx]. JAMA Ophthalmology (2021). High credibility.

A main argument for not recommending NSAIDs has been the lack of comparison with prednisolone drops, because they are theoretically more efficient than more potent corticosteroids owing to a greater intraocular bioavailability. Another argument was that the increased effect of adding NSAIDs to corticosteroids was likely caused by increased dosing. To address the first argument, we chose prednisolone rather than more potent corticosteroid drops for the combination groups. Our results showed that NSAID monotherapy was comparable to combined prednisolone and NSAID drops, even though the total dose was higher in the combination groups. This outcome corroborates the conclusions from other randomized trials that compared NSAID monotherapy with combinations of corticosteroid and NSAID eye drops; namely, there is no significant additional effect of adding topical corticosteroids to topical NSAIDs parallel to uncomplicated cataract surgery. It could be argued that a result of no statistical significance is not evidence that there is no difference between groups. However, our study was powered to detect differences between groups as small as 5 μm, which we expected to be within normal variation between 2 measurements. Differences in CST and CDVA between eye drop groups and controls were minimal, and CIs were narrow. Therefore, it is unlikely that a larger sample size would uncover any clinically relevant differences.

---

### Corticosteroids in total joint arthroplasty: the clinical practice guidelines of the American Association of Hip and Knee Surgeons, American Society of Regional Anesthesia and Pain Medicine, American Academy of Orthopaedic Surgeons, hip society, and knee society [^112AKfhN]. The Journal of Arthroplasty (2022). High credibility.

Corticosteroids in total joint arthroplasty — Response/Recommendation 2D states: "In the absence of reliable evidence, it is the opinion of the workgroup that ketorolac may be used in periarticular injection to reduce postoperative pain and may reduce postoperative opioid consumption without an increase in adverse events after primary total hip arthroplasty". Strength of Recommendation 2D: Consensus.

---

### Effect of ketorolac in intra-articular injection analgesia for postoperative pain in patients undergoing shoulder arthroscopy: a pilot-controlled clinical study [^112bHvYm]. Journal of Pain Research (2019). Medium credibility.

Discussion

Our findings confirmed that combining ketorolac with a multimodal drug regime produced more pain relief during the first 48 hours after surgery. Adding ketorolac resulted in a significant reduction in morphine consumption in the first 48 hours postoperatively. The initial analgesic desired time in the experimental group was also prolonged.

Postoperative pain

Effective postoperative pain relief permits earlier mobility and rehabilitation. Multimodal pain therapy is recommended as a sufficient analgesia, which increases the analgesic effect and duration. The rationale for this therapy is to maximize the additive or synergistic effects of different analgesics, but reduce concomitant side effects.

Preemptive oral analgesia usually results in a lower intensity and duration of afferent noxious stimuli, which minimizes the pain impulses from the surgical wound to the dorsal horn. In addition, it reduces secondary hyperalgesia by producing a lower threshold of dorsal root neurons and decreased receptive fields. We have previously assessed the effects of preemptive analgesia in total knee arthroplasty and confirmed that preemptive analgesia could improve analgesia, reduce inflammatory reactions, and accelerate functional recovery.

A systematic review concluded that morphine could reduce postoperative pain scores and analgesic consumption. Jaureguito et al reported that the efficacy and duration of action of intra-articular morphine depends on the dose. Denti et al reported that the combination of bupivacaine and morphine resulted in better pain relief in patients with anterior cruciate ligament reconstruction, and preemptive analgesia was better than postoperative anesthetic administration. Intra-articular injection of corticosteroids is a major conservative treatment. The peak analgesic effect starts at 12 hours postoperatively. Stein et al suggested that the inflammatory response usually disrupts the number and activation of opioid receptors present on sensory nerve terminals and reduces the analgesic effect. However, these changes are reversed within several hours. The reactive hyperemia of ischemia was found in inflamed synovial tissue, which could be reduced by triamcinolone acetonide. The pharmacokinetics of the analgesic drugs may explain the time of the maximum synergistic effect in the present results.

---

### Ketorolac in the era of cyclo-oxygenase-2 selective nonsteroidal anti-inflammatory drugs: a systematic review of efficacy, side effects, and regulatory issues [^116Hyzod]. Pain Medicine (2001). Low credibility.

Objective

The recent introduction of oral COX-2 selective NSAIDs with potential for perioperative use, and the ongoing development of intravenous formulations, stimulated a systemic review of efficacy, side effects, and regulatory issues related to ketorolac for management of postoperative analgesia.

Design

To examine the opioid dose sparing effect of ketorolac, we compiled published, randomized controlled trials of ketorolac versus placebo, with opioids given for breakthrough pain, published in English-language journals from 1986–2001. Odds ratios were computed to assess whether the use of ketorolac reduced the incidence of opioid side effects or improved the quality of analgesia.

Results

Depending on the type of surgery, ketorolac reduced opioid dose by a mean of 36% (range 0% to 73%). Seventy percent of patients in control groups experienced moderate-severe pain 1 hour postoperatively, while 36% of the control patients had moderate to severe pain 24 hours postoperatively. Analgesia was improved in patients receiving ketorolac in combination with opioids. However, we did not find a concomitant reduction in opioid side effects (e.g., nausea, vomiting). This may be due to studies having inadequate (to small) sample sizes to detect differences in the incidence of opioid related side effects. The risk for adverse events with ketorolac increases with high doses, with prolonged therapy (> 5 days), or invulnerable patients (e.g. the elderly). The incidence of serious adverse events has declined since dosage guidelines were revised.

Conclusions

Ketorolac should be administered at the lowest dose necessary. Analgesics that provide effective analgesia with minimal adverse effects are needed.

---

### Corticosteroids in total joint arthroplasty: the clinical practice guidelines of the American Association of Hip and Knee Surgeons, American Society of Regional Anesthesia and Pain Medicine, American Academy of Orthopaedic Surgeons, hip society, and knee society [^113Uu94o]. The Journal of Arthroplasty (2022). High credibility.

Corticosteroids in total joint arthroplasty — Response/Recommendation 2C states: "Ketorolac in periarticular injection is effective at reducing postoperative pain and may reduce opioid consumption without an increase in adverse events after primary total knee arthroplasty". Strength of Recommendation 2C: Moderate.

---

### Editorial commentary: periarticular and intra-articular injections may Do the right thing for patients' pain but may Be the wrong thing for their articular cartilage: Be careful [^112PErQ6]. Arthroscopy (2022). Medium credibility.

Periarticular and intra-articular injections are regularly used by orthopaedic surgeons both in the clinic and operative setting. These injections include the use of local anesthetics, nonsteroidal anti-inflammatories, steroidal anti-inflammatories, and other classes of pharmaceuticals. Local anesthetics can be injected alone or in conjunction with other pharmaceuticals to maximize pain control and to minimize narcotic use as part of a multimodal pain control algorithm. Use of intra-articular local anesthetics has been shown to improve postoperative pain scores and reduce intravenous and oral narcotic consumption and narcotic-related side effects, such as constipation, sedation, depression, respiratory depression, and long-term abuse potential. However, there have been reports of chondrolysis and other side effects from these injections. In general, it can be said that lidocaine is more chondrotoxic than bupivacaine and that methylprednisolone is more chondrotoxic when combined with either lidocaine or bupivacaine. Ropivacaine with steroid maybe less chondrotoxic, but this has yet to be established. It has been shown that ropivacaine with steroids may be toxic to chondrocytes as well as bovine tenocytes. In addition, it can be generalized that longer exposures, such as an indwelling, intra-articular catheter, are more chondrotoxic than shorter exposures, such as an intra-articular injection. Greater concentrations of lidocaine and bupivacaine (i.e., 1% vs 2% and 0.25% vs 0.5%, respectively) are more toxic to chondrocytes. Cellular morphine studies have resulted in conflicting reports of whether or not it is chondrotoxic. Both ketorolac and acetaminophen have been shown to decrease postoperative pain, but ketorolac also has been shown to be chondrotoxic in a human chondrocyte model. Doing the right thing for our patients' pain may be the wrong thing for their articular cartilage. Expansion of indications for these injections should be approached with caution.

---

### Ketorolac tromethamine (Sprix) [^114Xt3xT]. FDA (2024). Medium credibility.

1 INDICATIONS AND USAGE

SPRIX is indicated in adult patients for the short term (up to 5 days) management of moderate to moderately severe pain that requires analgesia at the opioid level.

Limitations of Use

Sprix is not for use in pediatric patients less than 2 years of age.

SPRIX is a nonsteroidal anti-inflammatory drug indicated in adult patients for the short term (up to 5 days) management of moderate to moderately severe pain that requires analgesia at the opioid level. (1)

---

### Prednisolone and ketorolac vs ketorolac monotherapy or sub-tenon prophylaxis for macular thickening in cataract surgery: a randomized clinical trial [^112aj1Ei]. JAMA Ophthalmology (2021). High credibility.

Limitations

This study has some limitations. We used a modified intention-to-treat approach for our analyses because some participants were excluded after allocation. We included patients with an expected low risk of complications, including macular edema, after cataract surgery, and the surgeons were experienced. Thus, our results may only apply to such patients and not patients with risk factors (eg, diabetes). The study did not include a corticosteroid eye drop monotherapy group and therefore did not compare corticosteroid drops with NSAID drops. Prednisolone, 1%, is less potent than other commonly used corticosteroid drops. Other approaches to dropless surgery exist that may prove more efficient than sub-Tenon dexamethasone depot as used in this study. Follow-up ended 3 months after surgery, and later presentations of PCME may not have been identified. The decision to add anti-inflammatory treatment was made by an unmasked physician.

---

### Effect of ketorolac in intra-articular injection analgesia for postoperative pain in patients undergoing shoulder arthroscopy: a pilot-controlled clinical study [^1144ZT1S]. Journal of Pain Research (2019). Medium credibility.

Conclusion

The current study shows that the combination of ketorolac and a multimodal drug regime (ropivacaine, morphine, and triamcinolone acetonide) leads to improved post-surgical pain scores, but further prospective controlled trials are necessary to allow for definite treatment recommendations.

---

### Ketorolac tromethamine, lidocaine hydrochloride, povidine iodine (ketorocaine L kit) [^113BLHfn]. FDA (2024). Medium credibility.

INDICATIONS AND USAGE

Carefully consider the potential benefits and risks of ketorolac tromethamine and other treatment options before deciding to use ketorolac. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS).

Acute Pain in Adult Patients

Ketorolac tromethamine is indicated for the short-term (≤ 5 days) management of moderately severe acute pain that requires analgesia at the opioid level, usually in a postoperative setting. Therapy should always be initiated with intravenous or intramuscular dosing of ketorolac tromethamine, and oral ketorolac tromethamine is to be used only as continuation treatment, if necessary.

The total combined duration of use of ketorolac tromethamine injection and oral ketorolac tromethamine is not to exceed 5 days of use because of the potential of increasing the frequency and severity of adverse reactions associated with the recommended doses (see WARNINGS, PRECAUTIONS, DOSAGE AND ADMINISTRATION, and ADVERSE REACTIONS). Patients should be switched to alternative analgesics as soon as possible, but ketorolac tromethamine therapy is not to exceed 5 days.

---

### Periarticular injection in total joint arthroplasty: the clinical practice guidelines of the American Association of Hip and Knee Surgeons, American Society of Regional Anesthesia and Pain Medicine, American Academy of Orthopaedic Surgeons, hip society, and knee society [^114mj1j4]. The Journal of Arthroplasty (2022). High credibility.

Periarticular injection in total joint arthroplasty (TJA) indicates that long-acting local anesthetics, corticosteroids and ketorolac are beneficial, but it is unclear at what dose/ concentration these medications should be used in combination; the benefit of epinephrine and clonidine, which are often added to modern periarticular injection cocktails, remain unknown and require future study, and the workgroup was unable to make a recommendation regarding the amount of periarticular injectate that should be injected, where it should be injected, and at what point during the primary TJA; future research should be focused on further understanding the dosing and volume of contents, and the location and timing of periarticular injection used during primary TJA.

---

### Corticosteroids in total joint arthroplasty: the clinical practice guidelines of the American Association of Hip and Knee Surgeons, American Society of Regional Anesthesia and Pain Medicine, American Academy of Orthopaedic Surgeons, hip society, and knee society [^1146amJX]. The Journal of Arthroplasty (2022). High credibility.

Ketorolac periarticular injection in primary total knee arthroplasty (TKA) — evidence scope: Three high-quality studies evaluated ketorolac used intraoperatively during primary TKA for postoperative pain, opioid consumption, and adverse events, but due to the limited number of studies and heterogeneity in data and timepoints no meta-analyses were able to be performed.

---

### PROSPECT guideline for rotator cuff repair surgery: systematic review and procedure-specific postoperative pain management recommendations [^111NPSCX]. Anaesthesia (2019). Medium credibility.

Results

The PRISMA flow chart demonstrating the search data are presented in Fig. 1. The methodological quality assessments of the 59 RCTs and one systematic review included for the final qualitative analysis are summarised in Table S1. The characteristics of the included studies are shown in Tables S2 and S3.

Figure 1
flow diagram of studies.

Systemic non‐opioid analgesics

In a placebo‐controlled study, Takada et al. looked into the pre‐operative use of a single dose of i.v. flurbiprofen 1 mg·kg⁻¹ in patients receiving intra‐articular ropivacaine at the end of the procedure 9. Pain scores were significantly lower at 0.5 h, 1 h, 2 h, 4 h and 6 h post‐surgery and buprenorphine consumption was lower within the first 2 h post‐surgery for flurbiprofen vs. placebo.

In patients receiving patient‐controlled analgesia (PCA) for the first 48 postoperative hours, Oh et al. 10 compared celecoxib, ibuprofen or tramadol for 2 weeks after surgery. Pain scores and rescue opioids were similar in the three groups at 3 days and 2 weeks after surgery. However, the 'tear' rates were higher in the celecoxib group, 24 months after surgery.

Cho et al. compared a multimodal pain regimen including pre‐operative oral oxycodone, acetaminophen, intra‐operative intra‐articular morphine, methylprednisolone acetate, ropivacaine 0.75%, and postoperative oral oxycodone, acetaminophen and celecoxib vs. postoperative oral celecoxib added to i.v. PCA with fentanyl and ketorolac 11. The multimodal pain regimen reduced pain scores immediately after surgery on postoperative days (POD) 3, 4 and 5. The multimodal protocol also reduced the likelihood for additional postoperative analgesia in the form of intramuscular (i.m.) diclofenac.

Bang et al. investigated in a placebo‐controlled manner the analgesic effects of oral gabapentin 300 mg administered 2 h pre‐operatively 12. Pain scores were significantly lower at 2 h, 6 h and 12 h after surgery, although fentanyl consumption did not differ between the gabapentin and placebo groups.

Desmet et al. conducted a placebo‐controlled study evaluating the effect of three different doses of i.v. dexamethasone on the duration of interscalene blockade 13. Postoperative pain scores and analgesic consumption were not significantly different between the groups, but dexamethasone 2.5 mg and 10 mg produced a significantly longer duration of analgesia.

---

### Evidence-based postoperative pain management after laparoscopic colorectal surgery [^112b6B5C]. Colorectal Disease (2013). Low credibility.

Aim

The aim of this systematic review was to evaluate the available literature on the management of pain after laparoscopic colorectal surgery.

Method

Randomized studies, published in English between January 1995 and July 2011, assessing analgesic and anaesthetic interventions in adults undergoing laparoscopic colorectal surgery, and reporting pain scores, were retrieved from the Embase and MEDLINE databases. The efficacy and adverse effects of the analgesic techniques was assessed. The recommendations were based on procedure-specific evidence from a systematic review and supplementary transferable evidence from other relevant procedures.

Results

Of the 170 randomized studies identified, 12 studies were included. Overall, all approaches including ketorolac, methylprednisolone, intraperitoneal instillation of ropivacaine, intravenous lidocaine infusion, intrathecal morphine and epidural analgesia improved pain relief, reduced opioid requirements and improved bowel function. However, there were significant differences in the study designs and the variables evaluated, precluding quantitative analysis. The L'Abbé plots of the data from the epidural analgesia studies included in this review indicate that the pain scores in the nonepidural groups, although higher than those in the epidural groups, were within an acceptable level (i.e. < 4/10).

Conclusion

Infiltration of surgical incisions with local anaesthetic at the end of surgery, systemic steroids, conventional nonsteroidal anti-inflammatory drugs or cyclooxygenase-2-selective inhibitors in combination with paracetamol with opioid used as rescue are recommended. Intravenous lidocaine infusion is recommended, but not as the first line of therapy. However, neuraxial blocks (i.e. epidural analgesia and spinal morphine) are not necessary based on high risk:benefit ratio.

---

### AAOS / METRC clinical practice guideline summary: pharmacologic, physical, and cognitive pain alleviation for musculoskeletal extremity / pelvis surgery [^112R5R7c]. The Journal of the American Academy of Orthopaedic Surgeons (2022). High credibility.

AAOS/METRC pain alleviation guideline — search strategy for musculoskeletal extremity/pelvis surgery includes intervention concepts such as cryotherapy, ice, thermotherapy, electrostimulation, acupuncture, massage, neuromuscular electrical stimulation, transcutaneous electrical nerve stimulation, and nerve stimulation, and also covers anesthesia and block techniques including local anesthesia, regional anesthesia, spinal anesthesia, nerve block*, adductor canal block*, ipack, fascia iliaca compartment block*, plexus block*, and neuraxial block*. The strategy also captures infiltration techniques and agents including infiltration analgesia, lidocaine, ropivacaine, bupivacaine, ketorolac, and epinephrine. Corticosteroid-related terms include corticosteroid*, prednisone, methylprednisolone, triamcinolone, glucocorticoid*, cortisone, and hydrocortisone. Background material and data summaries are available via the Pain Alleviation CPG eAppendix 1 and eAppendix 2.

---

### What is the role of a periarticular injection for knee arthroplasty patients receiving a multimodal analgesia regimen incorporating adductor canal and infiltration between the popliteal artery and capsule of the knee blocks? A randomized blinded placebo-controlled noninferiority trial [^112SMoEw]. Anesthesia and Analgesia (2024). Medium credibility.

Background

Optimal analgesic protocols for total knee arthroplasty (TKA) patients remain controversial. Multimodal analgesia is advocated, often including peripheral nerve blocks and/or periarticular injections (PAIs). If 2 blocks (adductor canal block [ACB] plus infiltration between the popliteal artery and capsule of the knee [IPACK]) are used, also performing PAI may not be necessary. This noninferiority trial hypothesized that TKA patients with ACB + IPACK + saline PAI (sham infiltration) would have pain scores that were no worse than those of patients with ACB + IPACK + active PAI with local anesthetic.

Methods

A multimodal analgesic protocol of spinal anesthesia, ACB and IPACK blocks, intraoperative ketamine and ketorolac, postoperative ketorolac followed by meloxicam, acetaminophen, duloxetine, and oral opioids was used. Patients undergoing primary unilateral TKA were randomized to receive either active PAI or control PAI. The active PAI included a deep injection, performed before cementation, of bupivacaine 0.25% with epinephrine, 30 mL; morphine; methylprednisolone; cefazolin; with normal saline to bring total volume to 64 mL. A superficial injection of 20 mL bupivacaine, 0.25%, was administered before closure. Control injections were normal saline injected with the same injection technique and volumes. The primary outcome was numeric rating scale pain with ambulation on postoperative day 1. A noninferiority margin of 1.0 was used.

Results

Ninety-four patients were randomized. NRS pain with ambulation at POD1 in the ACB + IPACK + saline PAI group was not found to be noninferior to that of the ACB + IPACK + active PAI group (difference = 0.3, 95% confidence interval, [-0.9 to 1.5], P = 0.120). Pain scores at rest did not differ significantly among groups. No significant difference was observed in opioid consumption between groups. Cumulative oral morphine equivalents through postoperative day 2 were 89 ± 40 mg (mean ± standard deviation), saline PAI, vs 73 ± 52, active PAI, P = 0.1. No significant differences were observed for worst pain, fraction of time in severe pain, pain interference, side-effects (nausea, drowsiness, itching, dizziness), quality of recovery, satisfaction, length of stay, chronic pain, and orthopedic outcomes.

Conclusions

For TKA patients given a comprehensive analgesic protocol, use of saline PAI did not demonstrate noninferiority compared to active PAI. Neither the primary nor any secondary outcomes demonstrated superiority for active PAI, however. As we cannot claim either technique to be better or worse, there remains flexibility for use of either technique.

---

### Ketorolac tromethamine (Acunivive 90) [^111Ycz7H]. FDA (2022). Medium credibility.

WARNING

Ketorolac tromethamine, a nonsteroidal anti-inflammatory drug (NSAID), is indicated for the short-term (up to 5 days in adults) management of moderately severe acute pain that requires analgesia at the opioid level. Oral ketorolac tromethamine is indicated only as continuation treatment following IV or IM dosing of ketorolac tromethamine, if necessary. The total combined duration of use of oral ketorolac tromethamine and ketorolac tromethamine injection should not exceed 5 days.

Ketorolac tromethamine is not indicated for use in pediatric patients and it is NOT indicated for minor or chronic painful conditions. Increasing the dose of ketorolac tromethamine beyond the label recommendations will not provide better efficacy but will increase the risk of developing serious adverse events.

GASTROINTESTINAL RISK

Ketorolac tromethamine can cause peptic ulcers, gastrointestinal bleeding and/or perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Therefore, ketorolac tromethamine is CONTRAINDICATED in patients with active peptic ulcer disease, in patients with recent gastrointestinal bleeding or perforation, and in patients with a history of peptic ulcer disease or gastrointestinal bleeding. Elderly patients are at greater risk for serious gastrointestinal events (see WARNINGS).

---

### Prednisolone and ketorolac vs ketorolac monotherapy or sub-tenon prophylaxis for macular thickening in cataract surgery: a randomized clinical trial [^1116HTwb]. JAMA Ophthalmology (2021). High credibility.

NSAID Monotherapy vs Combination of Topical Corticosteroid and NSAID

No differences were identified between NSAID monotherapy and the combination of prednisolone and NSAID drops regarding CST or CDVA at any postoperative visit after pooling combination groups (preoperative and postoperative prednisolone plus NSAID) and NSAID monotherapy groups (preoperative and postoperative NSAID). Intraocular pressure was lower for NSAID monotherapy 3 days and 3 weeks postoperatively compared with the combination of prednisolone and NSAID. No differences in IOP were identified 3 months postoperatively (eTable 9 in Supplement 3).

Preoperative vs Postoperative Initiation of Topical Treatment

We pooled groups with preoperative initiation (preoperative prednisolone plus NSAID and preoperative NSAID) and those with postoperative initiation (postoperative prednisolone plus NSAID and postoperative NSAID) of treatment. In this analysis, we identified no differences between preoperative or postoperative initiation of treatment for CST, CDVA, or IOP at any postoperative visit (eTable 10 in Supplement 3).

Sensitivity of Results

We found that our overall conclusions were not sensitive to handling of missing values, to restriction to the per-protocol population, or to inclusion, exclusion, or truncation of extreme outliers. In addition, postrandomization confounding from sex, age, and phacoemulsification energy was unlikely (eTables 1–6 in Supplement 3). Characteristics of participants with and without complete data are presented in eTable 11 in Supplement 3.

---

### Prednisolone and ketorolac vs ketorolac monotherapy or sub-tenon prophylaxis for macular thickening in cataract surgery: a randomized clinical trial [^117KhGEm]. JAMA Ophthalmology (2021). High credibility.

Key Points

Question

Is a combination of corticosteroid and nonsteroidal anti-inflammatory drug (NSAID) eye drops superior to NSAID eye drops alone or dropless surgery with a sub-Tenon dexamethasone depot in controlling postoperative central macular thickening after uncomplicated cataract surgery?

Findings

In this randomized clinical trial with 470 participants, no differences in central subfield thickness or visual acuity across treatment arms were identified, although approximately half of the group given the sub-Tenon depot received additional anti-inflammatory treatment.

Meaning

Therapy with NSAID plus corticosteroid eye drops was not superior to NSAID monotherapy or sub-Tenon depot for postoperative central macular thickening after uncomplicated cataract surgery.

---

### Adjuncts to local anesthetic wound infiltration for postoperative analgesia: a systematic review [^112VL7Cw]. Regional Anesthesia and Pain Medicine (2020). Medium credibility.

Local anesthetics (LAs) are commonly infiltrated into surgical wounds for postsurgical analgesia. While many adjuncts to LA agents have been studied, it is unclear which adjuncts are most effective for co-infiltration to improve and prolong analgesia. We performed a systematic review on adjuncts (excluding epinephrine) to local infiltrative anesthesia to determine their analgesic efficacy and opioid-sparing properties. Multiple databases were searched up to December 2019 for randomized controlled trials (RCTs) and two reviewers independently performed title/abstract screening and full-text review. Inclusion criteria were (1) adult surgical patients and (2) adjunct and LA agents infiltration into the surgical wound or subcutaneous tissue for postoperative analgesia. To focus on wound infiltration, studies on intra-articular, peri-tonsillar, or fascial plane infiltration were excluded. The primary outcome was reduction in postoperative opioid requirement. Secondary outcomes were time-to-first analgesic use, postoperative pain score, and any reported adverse effects. We screened 6670 citations, reviewed 126 full-text articles, and included 89 RCTs. Adjuncts included opioids, non-steroidal anti-inflammatory drugs, steroids, alpha-2 agonists, ketamine, magnesium, neosaxitoxin, and methylene blue. Alpha-2 agonists have the most evidence to support their use as adjuncts to LA infiltration. Fentanyl, ketorolac, dexamethasone, magnesium and several other agents show potential as adjuncts but require more evidence. Most studies support the safety of these agents. Our findings suggest benefits of several adjuncts to local infiltrative anesthesia for postoperative analgesia. Further well-powered RCTs are needed to compare various infiltration regimens and agents. PROTOCOL REGISTRATION: PROSPERO (CRD42018103851) (https://www.crd.york.ac.uk/prospero/display_record.php?RecordID = 103851).

---

### Ketorolac tromethamine (Acunivive 60) [^114g1VZU]. FDA (2022). Medium credibility.

WARNING

Ketorolac tromethamine, a nonsteroidal anti-inflammatory drug (NSAID), is indicated for the short-term (up to 5 days in adults) management of moderately severe acute pain that requires analgesia at the opioid level. Oral ketorolac tromethamine is indicated only as continuation treatment following IV or IM dosing of ketorolac tromethamine, if necessary. The total combined duration of use of oral ketorolac tromethamine and ketorolac tromethamine injection should not exceed 5 days.

Ketorolac tromethamine is not indicated for use in paediatric patients and it is NOT indicated for minor or chronic painful conditions. Increasing the dose of ketorolac tromethamine beyond the label recommendations will not provide better efficacy but will increase the risk of developing serious adverse events.

GASTROINTESTINAL RISK

Ketorolac tromethamine can cause peptic ulcers, gastrointestinal bleeding and/or perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Therefore, ketorolac tromethamine is CONTRAINDICATED in patients with active peptic ulcer disease, in patients with recent gastrointestinal bleeding or perforation, and in patients with a history of peptic ulcer disease or gastrointestinal bleeding. Elderly patients are at greater risk for serious gastrointestinal events (see WARNINGS).

---

### Nonsteroidal anti-inflammatory drugs in total joint arthroplasty: the clinical practice guidelines of the American Association of Hip and Knee Surgeons, American Society of Regional Anesthesia and Pain Medicine, American Academy of Orthopaedic Surgeons, hip society, and knee society [^1117e6Sw]. The Journal of Arthroplasty (2020). High credibility.

NSAIDs in primary total joint arthroplasty — We suggest future research on perioperative administration of NSAIDs focus on determining the optimal timing of the dosage and type of NSAID (selective or non-selective) to reduce the postoperative pain and/or reduction in opioid consumption. Because the current literature only has a single study investigating the use of a selective NSAID after discharge of a primary TKA, additional research is still necessary, and we suggest future research focus on the use of selective NSAIDs after discharge of primary hip and knee arthroplasties. If future research has been able to demonstrate the safe utilization of extended non-selective NSAIDs following primary TJA, then we would suggest the inclusion of non-selective NSAIDs in future research following discharge from primary TJA. Although we have robust literature to favor the effectiveness of IV ketorolac, we lack evidence to support the appropriate dosage that weighs the need to achieve adequate pain control while avoiding the risks of higher doses. The workgroup believes the largest impediment to wider adoption of NSAIDs relates to concerns surrounding the gastrointestinal and renal safety of the broad use of medications such as preoperative and postoperative oral NSAIDs with IV ketorolac, IV corticosteroids, and DVT prophylaxis of aspirin. As a result, we suggest continued monitoring for adverse events as NSAIDs become more widely adopted following primary TJA.

---

### The American Association for Thoracic Surgery congenital cardiac surgery working group 2021 consensus document on a comprehensive perioperative approach to enhanced recovery after pediatric cardiac surgery [^115kMmT9]. The Journal of Thoracic and Cardiovascular Surgery (2021). High credibility.

Ketorolac — perioperative use in pediatric cardiac surgery — might be opioid-sparing but has safety considerations, particularly in infants. When routinely administered for 48 hours after surgery in infants younger than 6 months, creatinine increased from baseline though values remained within normal limits, and ketorolac was associated with acute kidney injury in infants with preexisting renal dysfunction, concomitant aspirin use, or single-ventricle palliation, and should be used with caution in these settings. A randomized trial did not show increased risk of bleeding after pediatric cardiac surgery, and a recent study using ketorolac as part of an opioid-sparing regimen reported low incidence of postoperative acute kidney injury and bleeding.

---

### Ketorolac tromethamine [^117PwGsJ]. FDA (2024). Medium credibility.

Regarding the use of ketorolac tromethamine PO (also known as Acunivive, Toronova SUIK, Sprix, Acular, Toradol) in patients with intermittent hemodialysis:

- Do not use.
- Dose as in eGFR < 10 mL/min/1.73 m².
- Monitor serum concentrations. Monitor serum creatinine.

---

### Antiinflammatory effect of preoperative ketorolac in phacoemulsification [^113SExM1]. Journal of Cataract and Refractive Surgery (2002). Low credibility.

We report the antiinflammatory effect and efficacy of preoperative treatment with ketorolac in a patient with rheumatoid arthritis having phacoemulsification. This 70-year-old woman was on a maintenance dose of systemic methylprednisolone at the time of uneventful phacoemulsification in the left eye. She developed a sterile hypopyon on the first postoperative day and was treated aggressively with topical and systemic therapy, resulting in a gradual resolution of the inflammatory response. The patient subsequently had phacoemulsification in the right eye. The only significant difference in the preoperative management this time was that the patient received topical ofloxacin and ketorolac 4 days before surgery. The postoperative inflammatory response was much more controlled. The patient was continued on ketorolac and prednisolone acetate, resulting in the usual postoperative inflammatory response.

---

### French society of ENT (SFORL) guidelines. management of acute Bell's palsy [^113231ym]. European Annals of Otorhinolaryngology, Head and Neck Diseases (2020). Medium credibility.

The drug Methylprednisolone (also known as Medrol).

---

### Prednisolone and ketorolac vs ketorolac monotherapy or sub-tenon prophylaxis for macular thickening in cataract surgery: a randomized clinical trial [^1179fLJd]. JAMA Ophthalmology (2021). High credibility.

Introduction

Pseudophakic cystoid macular edema (PCME) is an important cause of unsatisfactory visual outcome after cataract surgery. It affects visual acuity after approximately 1% of surgical procedures. There is no common classification of PCME, and therefore estimates differ between studies. A meta-analysisreported that 4% to 25% had some degree of macular edema, even when prophylactic treatment was administered. It is believed that PCME is caused by the inflammatory response after cataract surgery, which disrupts the blood-ocular barrier leading to leakage of fluid into the retina. To control the inflammatory response and reduce the risk of PCME, prophylactic anti-inflammatory eye drops are prescribed parallel to cataract surgery.

The choice of anti-inflammatory prophylaxis is contested. Two types of drugs are available: corticosteroids and nonsteroidal anti-inflammatory drugs (NSAIDs). Corticosteroids inhibit phospholipases and thereby both prostaglandin and lipoxin synthesis, and NSAIDs selectively inhibit cyclooxygenase enzymes, which convert arachidonic acids to prostaglandins; however, meta-analyses, have found that NSAIDs are more effective in preventing PCME. It has been suggested that preoperative initiation of NSAID prophylaxis is beneficial, but to our knowledge, evidence from large randomized trials is missing.

Prophylactic treatment parallel to cataract surgery is traditionally administered as eye drops. Many patients have difficulties using eye drops and need assistance. Therefore, several dropless approaches have been suggested, and some studies, have found that the effectiveness of these dropless approaches is comparable to corticosteroid eye drop monotherapy. To our knowledge, no studies have compared a dropless approach with NSAID eye drops. The purpose of this study was to determine whether (1) combination of prednisolone and NSAID eye drops is superior in preventing macular thickening after uncomplicated cataract surgery compared with NSAID monotherapy and dropless surgery using a sub–Tenon capsule dexamethasone phosphate depot and (2) preoperative initiation of eye drop treatment is superior to initiating treatment on the day of surgery.

---

### Nonsteroidal anti-inflammatory drugs in total joint arthroplasty: the clinical practice guidelines of the American Association of Hip and Knee Surgeons, American Society of Regional Anesthesia and Pain Medicine, American Academy of Orthopaedic Surgeons, hip society, and knee society [^114YXkZu]. The Journal of Arthroplasty (2020). High credibility.

Intravenous ketorolac dosing after primary TJA — Recommendation 3B states that low-dose (15 mg) and high-dose (30 mg) administration of IV ketorolac immediately postoperatively are equivalent at reducing pain and opioid consumption postoperatively (within the first six hours) following primary TJA; Strength of Recommendation 3B: Moderate.

---

### Efficacy and safety of steroid use for postoperative pain relief. update and review of the medical literature [^117EsRxU]. The Journal of Bone and Joint Surgery: American Volume (2006). Low credibility.

Despite the availability of various analgesic regimens, patient surveys have indicated that moderate-to-severe postoperative pain is still poorly managed. The use of corticosteroids for postoperative pain relief, although popular, has yet to gain wider acceptance because of concerns over side effects, in particular adrenal suppression, osteonecrosis, impaired wound-healing, and concerns about efficacy. The medical literature provides evidence that should substantially decrease these concerns with regard to low and short-dose applications. The results of randomized trials have shown low, short-dose corticosteroid regimens to be safe and effective for reducing postoperative pain. There is strong, grade-A evidence supporting the use of corticosteroids in multimodal analgesia protocols to contribute to the postoperative recovery of the patient by minimizing opioid doses and therefore side effects. However, the optimal mode, dose, and timing of administration remain unclear.

---

### An in vitro evaluation of the anti-inflammatory effects of platelet-rich plasma, ketorolac, and methylprednisolone [^113qfFQQ]. Arthroscopy (2013). Low credibility.

Purpose

The purpose of this study was to quantify the extent of the anti-inflammatory effect of platelet-rich plasma (PRP) in a controlled in vitro environment.

Methods

Through the stimulation of human umbilical vein endothelial cells with inflammatory cytokines (tumor necrosis factor α and interferon γ), cell adhesion molecule expression (E-selectin, vascular cell adhesion molecule, and human leukocyte antigen DR) and PRP's anti-inflammatory effect can be measured. PRP was produced from 3 individuals using a single-spin (PRPLP) process. Treatment groups include negative (unstimulated) controls, positive (stimulated) controls, ketorolac tromethamine, methylprednisolone, PRP, ketorolac-PRP, and methylprednisolone-PRP. A fluorescence assay of the cellular inflammation markers was measured by the BioTek Synergy HT plate reader (BioTek Instruments, Winooski, VT) at 0, 1, 2, and 5 days.

Results

At days 2 and 5, methylprednisolone treatment showed a 2.1- to 5.8-fold reduction (P < .05) in inflammation markers over PRP. In addition, PRP and ketorolac showed a 1.4- to 2.5-fold reduction (P < .05) in cellular inflammation markers over the control. There was no statistically significant difference between ketorolac and PRP.

Conclusions

Although PRP and ketorolac reduced cellular inflammation markers (E-selectin, vascular cell adhesion molecule, and human leukocyte antigen DR) compared with control, neither caused as great a reduction as methylprednisolone.

Clinical Relevance

Although PRP and ketorolac did not produce as significant a reduction in cellular inflammation markers as methylprednisolone, they reduced cellular inflammation compared with the control. These agents may have clinical application as injectable anti-inflammatory medications.

---

### Prednisolone and ketorolac vs ketorolac monotherapy or sub-tenon prophylaxis for macular thickening in cataract surgery: a randomized clinical trial [^112oJjuc]. JAMA Ophthalmology (2021). High credibility.

Discussion

We investigated the effect of anti-inflammatory prophylaxis on macular thickening after uncomplicated cataract surgery in a randomized clinical study that evaluated the additive effect of prednisolone to NSAID eye drops in a fashion that allowed us to compare the effect of initiating treatment preoperatively with initiation on the day of surgery. In addition, we evaluated the effect of dropless surgery using a sub-Tenon dexamethasone depot. We found that NSAID plus corticosteroid drops were not superior to NSAID monotherapy or sub-Tenon dexamethasone depot for postoperative central macular thickening after uncomplicated cataract surgery.

One of the primary purposes of prescribing an anti-inflammatory prophylactic treatment in parallel with cataract surgery is to prevent PCME. Pseudophakic cystoid macular edema is infrequent and heterogeneously defined, which makes it difficult to use the incidence as an outcome in clinical trials. Instead, the CST measured with optical coherence tomography is generally accepted as a measure for comparing efficacy of prophylactic regimens. We did not find differences in CST between groups receiving NSAID monotherapy or a combination of NSAID and prednisolone. A large European multicenter trialcompared corticosteroid monotherapy (dexamethasone, 0.1%) with NSAID monotherapy (bromfenac, 0.09%) and a combination of both and found no significant differences between the combination of corticosteroid and NSAID and NSAID monotherapy, whereas dexamethasone monotherapy resulted in increased macular thickness 6 weeks postoperatively. However, NSAID monotherapy is still controversial for prophylactic treatment after cataract surgery, especially in the US, and NSAIDs are not recommended by the American Academy of Ophthalmology.

---

### Clinical practice guideline: opioid prescribing for analgesia after common otolaryngology operations [^114y2TQC]. Otolaryngology — Head and Neck Surgery (2021). High credibility.

Multimodal perioperative analgesia — preoperative strategies include acetaminophen, "NSAID or COX-2 (celecoxib)", gabapentinoid (off-label), and intravenous options such as "IV ketorolac", "IV or rectal acetaminophen", "IV ketamine", "IV clonidine", and "IV steroids", with regional techniques including "Incisional lidocaine injection" and "Superficial cervical plexus blocks". Postoperative options include "Acetaminophen", "NSAID or COX-2 (celecoxib)", "Gabapentinoid (off-label)", and the "Lowest dose of short-acting opiate for breakthrough pain", and "Postoperatively, most references recommend continuous treatment with NSAID or COX-2 inhibitor and acetaminophen", while "Short-acting opioids can be used for breakthrough pain". Additional notes state that "Celecoxib does not interfere with platelet function and has no effect on bleeding time", that intraoperative choices "include intravenous (IV) ketorolac, IV or rectal acetaminophen, IV ketamine, clonidine, and IV steroids", that local anesthetic injection "has also been shown to add to the multimodal analgesia effect", and that "Gabapentinoid has been used in both preoperative and postoperative settings", with an "MA of 17 RCTs (1793 patients)".

---

### Nonsteroidal anti-inflammatory drugs in total joint arthroplasty: the clinical practice guidelines of the American Association of Hip and Knee Surgeons, American Society of Regional Anesthesia and Pain Medicine, American Academy of Orthopaedic Surgeons, hip society, and knee society [^111RFEHZ]. The Journal of Arthroplasty (2020). High credibility.

Evidence base for IV ketorolac in TJA — The guideline reports reviewing seven randomized clinical trials, including four high quality and three moderate quality studies, to assess the ability of IV ketorolac to reduce postoperative pain and/or opioid consumption following TJA, and notes that qualitative analysis consistently demonstrated statistically favorable outcomes for IV ketorolac.

---

### Sulopenem etzadroxil and probenecid (Orlynvah) [^112pMmuN]. FDA (2025). Medium credibility.

Contraindication regarding the use of sulopenem / probenecid PO (also known as Orlynvah) and concomitant use of ketorolac tromethamine or ketoprofen: use caution in patients taking other drugs that are dependent on OAT1/3 for elimination.

---

### Prednisolone and ketorolac vs ketorolac monotherapy or sub-tenon prophylaxis for macular thickening in cataract surgery: a randomized clinical trial [^1155cLe7]. JAMA Ophthalmology (2021). High credibility.

Preoperative initiation of therapy did not result in decreased CST compared with postoperative initiation, even after pooling relevant groups. A previous randomized clinical trialconcluded that preoperative initiation of ketorolac, 0.4%, was advantageous in the early postoperative period but showed no significant effects on long-term outcomes. No data on central macular thickness were reported, and the groups were small. We found no effect of preoperative initiation on any outcome measures.

In the sub-Tenon group, CST was significantly increased 3 weeks postoperatively compared with the preoperative prednisolone plus NSAID group, but the difference was no longer significant 3 months after surgery. More than half of the participants in the sub-Tenon group required additional topical anti-inflammatory treatment during the study period, which might explain why no difference in CST was found at 3 months. Other randomizedand nonrandomized, studies have found comparable results between dropless surgery and corticosteroid eye drop monotherapy, but we were unable to locate reports comparing dropless surgery with combined corticosteroid and NSAID eye drops or NSAID monotherapy. We used a sub-Tenon depot of a highly potent corticosteroid, dexamethasone phosphate, and refrained from using triamcinolone, which has a much longer period of action, because of fear of sustained IOP elevations. Although it was safe to administer the sub-Tenon dexamethasone depot, it was not comparable to NSAID or prednisolone plus NSAID in preventing macular thickening after cataract surgery. In patients with suspected poor adherence with topical treatment, placing a depot of corticosteroid during surgery could serve as adjuvant therapy. However, IOP should be monitored regularly if triamcinolone is used.

Intraocular pressure was lower during eye drop treatment in groups who did not use corticosteroid drops compared with those who did. However, the mean IOP in all groups was low in the reference range, and there were no elevations of greater than 25 mm Hg at any postoperative visit. There were no differences in visual acuity at any time point, but adverse events and unscheduled visits were more often encountered in the sub-Tenon group.

---

### Aspirin, steroidal and non-steroidal anti-inflammatory drugs for the treatment of Alzheimer's disease [^116QsCdx]. The Cochrane Database of Systematic Reviews (2012). Low credibility.

Background

Alzheimer's disease (AD) is the most common form of dementia. The incidence of AD rises exponentially with age and its prevalence will increase significantly worldwide in the next few decades. Inflammatory processes have been suspected in the pathogenesis of the disease.

Objectives

To review the efficacy and side effects of aspirin, steroidal and non-steroidal anti-inflammatory drugs (NSAIDs) in the treatment of AD, compared to placebo.

Search Methods

We searched ALOIS: the Cochrane Dementia and Cognitive Improvement Group's Specialized Register on 12 April 2011 using the terms: aspirin OR "cyclooxygenase 2 inhibitor" OR aceclofenac OR acemetacin OR betamethasone OR celecoxib OR cortisone OR deflazacort OR dexamethasone OR dexibruprofen OR dexketoprofen OR diclofenac sodium OR diflunisal OR diflusinal OR etodolac OR etoricoxib OR fenbufen OR fenoprofen OR flurbiprofen OR hydrocortisone OR ibuprofen OR indometacin OR indomethacin OR ketoprofen OR lumiracoxib OR mefenamic OR meloxicam OR methylprednisolone OR nabumetone OR naproxen OR nimesulide OR "anti-inflammatory" OR prednisone OR piroxicam OR sulindac OR tenoxicam OR tiaprofenic acid OR triamcinolone OR NSAIDS OR NSAID. ALOIS contains records of clinical trials identified from monthly searches of a number of major healthcare databases (including MEDLINE, EMBASE, PsycINFO, CINAHL, LILACS), numerous trial registries (including national, international and pharmacuetical registries) and grey literature sources.

Selection Criteria

All randomised controlled trials assessing the efficacy of aspirin, steroidal and non-steroidal anti-inflammatory drugs in AD.

Data Collection and Analysis

One author assessed risk of bias of each study and extracted data. A second author verified data selection.

Main Results

Our search identified 604 potentially relevant studies. Of these, 14 studies (15 interventions) were RCTs and met our inclusion criteria. The numbers of participants were 352, 138 and 1745 for aspirin, steroid and NSAIDs groups, respectively. One selected study comprised two separate interventions. Interventions assessed in these studies were grouped into four categories: aspirin (three interventions), steroids (one intervention), traditional NSAIDs (six interventions), and selective cyclooxygenase-2 (COX-2) inhibitors (five interventions). All studies were evaluated for internal validity using a risk of bias assessment tool. The risk of bias was low for five studies, high for seven studies, and unclear for two studies. There was no significant improvement in cognitive decline for aspirin, steroid, traditional NSAIDs and selective COX-2 inhibitors. Compared to controls, patients receiving aspirin experienced more bleeding while patients receiving steroid experienced more hyperglycaemia, abnormal lab results and face edema. Patients receiving NSAIDs experienced nausea, vomiting, elevated creatinine, elevated LFT and hypertension. A trend towards higher death rates was observed among patients treated with NSAIDS compared with placebo and this was somewhat higher for selective COX-2 inhibitors than for traditional NSAIDs.

Authors' Conclusions

Based on the studies carried out so far, the efficacy of aspirin, steroid and NSAIDs (traditional NSAIDs and COX-2 inhibitors) is not proven. Therefore, these drugs cannot be recommended for the treatment of AD.

---

### Ketorolac tromethamine [^113mDS1f]. FDA (2025). Medium credibility.

Diuretics

Clinical studies, as well as postmarketing observations, have shown that ketorolac tromethamine can reduce the natriuretic effect of furosemide and thiazides in some patients. This response has been attributed to inhibition of renal prostaglandin synthesis. During concomitant therapy with NSAIDs, the patient should be observed closely for signs of renal failure (see WARNINGS – Renal Effects), as well as to assure diuretic efficacy.

Probenecid

Concomitant administration of oral ketorolac tromethamine and probenecid resulted in decreased clearance and volume of distribution of ketorolac and significant increases in ketorolac plasma levels (total AUC increased approximately three-fold from 5.4 to 17.8 mcg/h/mL) and terminal half-life increased approximately two-fold from 6.6 to 15.1 hours. Therefore, concomitant use of ketorolac tromethamine and probenecid is contraindicated.

Lithium

NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance. The mean minimum lithium concentration increased 15% and the renal clearance was decreased by approximately 20%. These effects have been attributed to inhibition of renal prostaglandin synthesis by the NSAID. Thus, when NSAIDs and lithium are administered concurrently, subjects should be observed carefully for signs of lithium toxicity.

Methotrexate

NSAIDs have been reported to competitively inhibit methotrexate accumulation in rabbit kidney slices. This may indicate that they could enhance the toxicity of methotrexate. Caution should be used when NSAIDs are administered concomitantly with methotrexate.

ACE Inhibitors/Angiotensin II Receptor Antagonists

Concomitant use of ACE inhibitors and/or angiotensin II receptor antagonists may increase the risk of renal impairment, particularly in volume-depleted patients.

Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE inhibitors and/or angiotensin II receptor antagonists. This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE inhibitors and/or angiotensin II receptor antagonists.

Antiepileptic Drugs

Sporadic cases of seizures have been reported during concomitant use of ketorolac tromethamine and antiepileptic drugs (phenytoin, carbamazepine).

Psychoactive Drugs

Hallucinations have been reported when ketorolac tromethamine was used in patients taking psychoactive drugs (fluoxetine, thiothixene, alprazolam).

Pentoxifylline

When ketorolac tromethamine is administered concurrently with pentoxifylline, there is an increased tendency to bleeding.

---

### Lidocaine infusions for refractory chronic migraine: a retrospective analysis [^113CtVRG]. Regional Anesthesia and Pain Medicine (2022). Medium credibility.

Introduction

Patients with refractory chronic migraine have poor quality of life. Intravenous infusions are indicated to rapidly 'break the cycle' of pain. Lidocaine infusions may be effective but evidence is limited.

Methods

The records of 832 hospital admissions involving continuous multiday lidocaine infusions for migraine were reviewed. All patients met criteria for refractory chronic migraine. During hospitalization, patients received additional migraine medications including ketorolac, magnesium, dihydroergotamine, methylprednisolone, and neuroleptics. The primary outcome was change in headache pain from baseline to hospital discharge. Secondary outcomes measured at the post-discharge office visit (25–65days after treatment) included headache pain and the number of headache days, and percentage of sustained responders. Percentage of acute responders, plasma lidocaine levels, and adverse drug effects were also determined.

Results

In total, 609 patient admissions met criteria. The mean age was 46 ± 14years; 81.1% were female. Median pain rating decreased from baseline of 7.0 (5.0–8.0) to 1.0 (0.0–3.0) at end of hospitalization (p < 0.001); 87.8% of patients were acute responders. Average pain (N = 261) remained below baseline at office visit 1 (5.5 (4.0–7.0); p < 0.001). Forty-three percent of patients were sustained responders at 1month. Headache days (N = 266) decreased from 26.8 ± 3.9 at baseline to 22.5 ± 8.3 at the post-discharge office visit (p < 0.001). Nausea and vomiting were the most common adverse drug effects and all were mild.

Conclusion

Lidocaine infusions may be associated with short-term and medium-term pain relief in refractory chronic migraine. Prospective studies should confirm these results.

---

### Ketorolac tromethamine, lidocaine hydrochloride, povidine iodine (ketorocaine L kit) [^1179uho8]. FDA (2024). Medium credibility.

WARNING

Ketorolac tromethamine, a nonsteroidal anti-inflammatory drug (NSAID), is indicated for the short-term (up to 5 days in adults) management of moderately severe acute pain that requires analgesia at the opioid level. Oral ketorolac tromethamine is indicated only as continuation treatment following intravenous or intramuscular dosing of ketorolac tromethamine, if necessary. The total combined duration of use of oral ketorolac tromethamine and ketorolac tromethamine injection should not exceed 5 days.

Ketorolac tromethamine is not indicated for use in pediatric patients and it is NOT indicated for minor or chronic painful conditions. Increasing the dose of ketorolac tromethamine beyond the label recommendations will not provide better efficacy but will increase the risk of developing serious adverse events.

GASTROINTESTINAL RISK

- Ketorolac tromethamine can cause peptic ulcers, gastrointestinal bleeding and/or perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Therefore, ketorolac tromethamine is CONTRAINDICATED in patients with active peptic ulcer disease, in patients with recent gastrointestinal bleeding or perforation, and in patients with a history of peptic ulcer disease or gastrointestinal bleeding. Elderly patients are at greater risk for serious gastrointestinal events (see WARNINGS).

---

### Efficacy and safety of non-steroidal anti-inflammatory drugs (NSAIDs) for the treatment of acute pain after orthopedic trauma: a practice management guideline from the Eastern Association for the Surgery of Trauma and the orthopedic trauma association [^115Eqvtm]. Trauma Surgery & Acute Care Open (2023). High credibility.

Regarding medical management for rib fracture, more specifically with respect to pain management (NSAIDs), AOTA/EAST 2023 guidelines recommend to consider administering NSAIDs (such as ketorolac) for pain management in adult patients with a traumatic fracture.

---

### Best practices guidelines for acute pain management in trauma patients [^11688bKK]. ACS (2020). High credibility.

Pain management in older adults — potentially inappropriate analgesics: NSAIDs should "Avoid chronic use unless alternatives are not available. When used, combine with gastroprotective agent (e.g. PPI or misoprostol)" because of "Increased risk of upper gastrointestinal bleeding", with a footnote indicating "Other than COX-2 selective agents (e.g., celecoxib)". Indomethacin and ketorolac are "Avoid" due to "Increased risk of upper gastrointestinal bleeding (more than other NSAIDs) and acute kidney injury". Skeletal muscle relaxants are "Avoid" as they are "Poorly tolerated due to anticholinergic effects". Tramadol, serotonin norepinephrine reuptake inhibitors (SNRI), selective serotonin reuptake inhibitors (SSRI), and tricyclic antidepressants (TCA) are "Use with caution" because they "May increase risk of SIADH or hyponatremia".

---

### Effect of perioperative dexamethasone and different NSAIDs on anastomotic leak risk: a propensity score analysis [^114ns4az]. World Journal of Surgery (2016). Low credibility.

Per- and postoperative use of steroids and NSAIDs

The specific dose and days of ordination of NSAIDs and steroids prescribed and received by the patient within the first 5 days after the operation were recorded, as well as steroids and NSAIDs that were already in routine use before the operation. The usual NSAIDs ordinated in the postoperative phase were either ketorolac or diclofenac. Ketorolac (30 mg) was ordinated as a single i.v. dose postoperatively on the same day as the operation, with the exception of six patients who received 15–50 mg in one or two extra doses on day 0 and one patient who received 40 mg daily during days 1–2, and the administration was defined as received or not received. Diclofenac was perorally administered as tablets from day 0, and we registered the dose of diclofenac for each day, starting with the day of operation (day 0) up to postoperative day 5 (POD 5). The use of diclofenac for this time period was defined as received or not received in the further analyses, irrespective of cumulative dose, startup day, and days of administration. Dexamethasone was the usual steroid that was ordinated per- or postoperatively, and then as single doses of 4, 8,16 or 24 mg. Administration of dexamethasone was defined as received or not received, irrespective of doses. Seven patients using steroids as a regular medication before the operation were included, and this was registered as a variable in the patient characteristics and adjusted for in the propensity score analysis.

Patient and perioperative characteristics

We registered the following patient and perioperative characteristics in this study: age, sex, body mass index (BMI, kg/m²), preoperative albumin level (g/L), smoking, American Society of Anesthesiologists' score (ASA score), operation for malignant or benign disease, preoperative radiotherapy, elective or emergency operation, open or laparoscopic surgery, type of anastomosis, construction of diverting stoma, use of a vasopressor, blood transfusion, and regular steroid medication. The use of a postoperative vasopressor was applied as an indirect marker for low blood pressure in the early postoperative phase. A vasopressor is defined as at least one ordination of epinephrine or norepinephrine during the first day after the operation.

---

### Prednisolone and ketorolac vs ketorolac monotherapy or sub-tenon prophylaxis for macular thickening in cataract surgery: a randomized clinical trial [^1154jQBs]. JAMA Ophthalmology (2021). High credibility.

Methods

Design and Intervention

This study was a randomized clinical trial comparing 5 different regimens for anti-inflammatory prophylaxis parallel to uncomplicated cataract surgery. The trial protocol and statistical analysis plan are found in Supplement 1 and Supplement 2, respectively. The control group received a combination of corticosteroid and NSAID eye drops, initiated 3 days before surgery (preoperative prednisolone plus NSAID group). Comparison groups received a combination of corticosteroid and NSAID drops initiated on the day of surgery (postoperative prednisolone plus NSAID group), NSAID eye drop monotherapy initiated 3 days before surgery or on the day of surgery (preoperative NSAID and postoperative NSAID groups, respectively), and sub-Tenon depot of dexamethasone administered at the conclusion of surgery (sub-Tenon group). Participants in the sub-Tenon group were not given anti-inflammatory drops. Corticosteroid drops were prednisolone acetate, 1% (Pred Forte; Allergan); NSAID drops, ketorolac tromethamine, 0.5% (Acular; Allergan); and sub-Tenon depot, 0.5 mL of dexamethasone phosphate, 4 mg/mL (Dexamethasone Krka [Krka] or Dexavital [Vital Pharma Nordic]). All drops were administered 3 times per day until 3 weeks postoperatively, and adherence was monitored by asking participants, in an unstructured manner, if they were taking their drops; no formal recording of compliance was collected. Ethics committee approval was obtained from the Committee on Health Research Ethics, Capital Region, Denmark. The study was approved by the Danish Medicines Agency and the Danish Data Protection Agency. Accordance with the good clinical practice quality standard was monitored by the good clinical practice unit at Copenhagen University Hospital, Copenhagen, Denmark. The study was conducted in accordance with the Declaration of Helsinki, and all participants provided written informed consent. Participants received no incentives or compensation for participation. This study followed the Consolidated Standards of Reporting Trials reporting guideline.

---

### Nonsteroidal anti-inflammatory drugs in total joint arthroplasty: the clinical practice guidelines of the American Association of Hip and Knee Surgeons, American Society of Regional Anesthesia and Pain Medicine, American Academy of Orthopaedic Surgeons, hip society, and knee society [^114rKFzQ]. The Journal of Arthroplasty (2020). High credibility.

Intravenous ketorolac in primary total joint arthroplasty (TJA) — Recommendation 3A states that administration of IV ketorolac preoperatively, intraoperatively, or within 24 hours postoperatively reduces pain and opioid consumption postoperatively (within the first 48 hours) following primary TJA; Strength of Recommendation 3A: Strong.

---

### Local infiltration of analgesics at surgical wound to reduce postoperative pain after laparotomy in rats [^116J7n1x]. Regional Anesthesia and Pain Medicine (2016). Low credibility.

Background and Objectives

There is an increasing use of local infiltration analgesia (LIA) to reduce postoperative pain. Despite widespread use of LIA, wide variations in drug combinations and concomitant use of systemic analgesics have made it difficult to determine the optimal drug combinations for LIA. Using a previously validated rat laparotomy model, the optimal LIA combination of medications to reduce postoperative pain was determined.

Methods

Laparotomy was performed in an adult rat model under isoflurane anesthesia. During surgery, combinations of bupivacaine, ketorolac, and dexamethasone were injected over the sutured muscle wound before skin closing, and compared to saline (placebo). The same medications were injected systemically as controls. Postoperative pain was assessed by measuring spontaneous rearing activity.

Results

A high-dose 3-drug LIA combination (50 μL of bupivacaine 0.75%, ketorolac 6.0 mg/mL, and dexamethasone 2.0 mg/mL) increased rearing (decreased pain) at 2 hours (P = 0.0032) postsurgery compared to saline. However, the same 3 drugs injected systemically had a similar analgesic effect (P = 0.0002). Bupivacaine 0.75% alone was not effective for LIA. When low-dose (9-fold reduction) 3-drug LIA combination was used, LIA increased rearing (P = 0.0034) whereas the same 3 drugs injected systemically had no effect. Low-dose LIA ketorolac/dexamethasone (2-drug combination) also increased rearing (P = 0.0393).

Conclusions

Our animal study suggests that clinical trials with low-dose LIA combinations of local anesthetic, nonsteroidal anti-inflammatory drug, and corticosteroid may be useful for reducing postoperative pain after laparotomy.

---

### Best practices guidelines for acute pain management in trauma patients [^113snEKB]. ACS (2020). High credibility.

Pharmacologic analgesia — nonsteroidal anti-inflammatory drugs (NSAIDs): Ibuprofen has a maintenance dose of 400 mg q6h with maximum 2,400 mg/day; ketorolac 10 mg q6h with maximum 40 mg/day for no more than 5 days; and celecoxib 100 mg q12h with maximum 400 mg/day. Listed cautions include cardiac history (CI), GI bleeding (CI), fracture (P), renal dysfunction (P); single dose ibuprofen > 400 mg or ketorolac > 10 mg not recommended; and COX-2 selective NSAIDs reduce risk of major and upper gastrointestinal bleeding vs. nonselective.

---

### Ketorolac for postoperative pain in children [^116qbZyz]. The Cochrane Database of Systematic Reviews (2018). Low credibility.

Background

Children who undergo surgical procedures in ambulatory and inpatient settings are at risk of experiencing acute pain. Nonsteroidal anti-inflammatory drugs (NSAIDs) can reduce moderate to severe pain without many of the side effects associated with opioids. However, NSAIDs may cause bleeding, renal and gastrointestinal toxicity, and potentially delay wound and bone healing. Intravenous administration of ketorolac for postoperative pain in children has not been approved in many countries, but is routinely administered in clinical practise.

Objectives

To assess the efficacy and safety of ketorolac for postoperative pain in children.

Search Methods

We searched the following databases, without language restrictions, to November 2017: CENTRAL (The Cochrane Library 2017, Issue 10); MEDLINE, Embase, and LILACS. We also checked clinical trials registers and reference lists of reviews, and retrieved articles for additional studies.

Selection Criteria

We included randomised controlled trials that compared the analgesic efficacy of ketorolac (in any dose, administered via any route) with placebo or another active treatment, in treating postoperative pain in participants zero to 18 years of age following any type of surgery.

Data Collection and Analysis

We used standard methodological procedures expected by Cochrane. Two review authors independently considered trials for inclusion in the review, assessed risk of bias, and extracted data. We analyzed trials in two groups; ketorolac versus placebo, and ketorolac versus opioid. However, we performed limited pooled analyses. We assessed the overall quality of the evidence for each outcome using GRADE, and created a 'Summary of findings' table.

Main Results

We included 13 studies, involving 920 randomised participants. There was considerable heterogeneity among study designs, including the comparator arms (placebo, opioid, another NSAID, or a different regimen of ketorolac), dosing regimens (routes and timing of administration, single versus multiple dose), outcome assessment methods, and types of surgery. Mean study population ages ranged from 356 days to 13.9 years. The majority of studies chose a dose of either 0.5 mg/kg (as a single or multiple dose regimen) or 1 mg/kg (single dose with 0.5 mg/kg for any subsequent doses). One study administered interventions intraoperatively; the remainder administered interventions postoperatively, often after the participant reported moderate to severe pain. There were insufficient data to perform meta-analysis for either of our primary outcomes: participants with at least 50% pain relief; or mean postoperative pain intensity. Four studies individually reported statistically significant reductions in pain intensity when comparing ketorolac with placebo, but the studies were small and had various risks of bias, primarily due to incomplete outcome data and small sample sizes. We found limited data available for the secondary outcomes of participants requiring rescue medication and opioid consumption. For the former, we saw no clear difference between ketorolac and placebo; 74 of 135 (55%) participants receiving ketorolac required rescue analgesia in the post-anaesthesia care unit (PACU) versus 81 of 127 (64%) receiving placebo (relative risk (RR) 0.85, 95% confidence interval (CI) 0.71 to 1.00, P = 0.05; 4 studies, 262 participants). For opioid consumption in the PACU, we saw no clear difference between ketorolac and placebo (P = 0.61). For the time period zero to four hours after administration of the interventions, participants receiving ketorolac received 1.58 mg less intravenous morphine equivalents than those receiving placebo (95% CI -2.58 mg to -0.57 mg, P = 0.002; 2 studies, 129 participants). However, we are uncertain whether ketorolac has an important effect on opioid consumption, as the data were sparse and the results were inconsistent. Only one study reported data for opioid consumption when comparing ketorolac with an opioid. There were no clear differences between the ketorolac and opioid group at any time point. There were no data assessing this outcome for the comparison of ketorolac with another NSAID. There were insufficient data to allow us to analyze overall adverse event or serious adverse event rates. Although the majority of serious adverse events reported in those receiving ketorolac involved bleeding, the number of events was too low to conclude that bleeding risk was increased in those receiving ketorolac perioperatively. There was not a statistically significant increase in event rates for any specific adverse event, either in pooled analysis or in single studies, when comparing ketorolac and placebo. When comparing ketorolac with opioids or other NSAIDs, there were too few data to make any conclusions regarding event rates. Lastly, withdrawals due to adverse events were vary rare in all groups, reflecting the acute nature of such studies. We assessed the quality of evidence for all outcomes for each comparison (placebo or active) as very low, due to issues with risk of bias in individual studies, imprecision, heterogeneity between studies, and low overall numbers of participants and events.

Authors' Conclusions

Due to the lack of data for our primary outcomes, and the very low-quality evidence for secondary outcomes, the efficacy and safety of ketorolac in treating postoperative pain in children were both uncertain. The evidence was insufficient to support or reject its use.

---

### Methylprednisolone (methylprednisolone sodium succinate) [^1169bJSk]. FDA (2024). Medium credibility.

The drug Methylprednisolone sodium succinate (also known as Solu-Medrol).

---

### Best practices guidelines for acute pain management in trauma patients [^111zsNQQ]. ACS (2020). High credibility.

Table 10 — Perioperative multimodal pain management lists nonpharmacologic strategies (e.g., positioning, splinting, heat/cold, calming); IV opioids (fentanyl, hydromorphone, morphine, sufentanil); NMDA antagonists (e.g., ketamine, methadone); NSAIDs (PO/IV) with caution regarding bleeding/healing risk, especially ketorolac; APAP (IV/oral); local anesthetic (for painful local injuries or procedures); regional blocks; alpha-2 agonists (e.g., dexmedetomidine); and lidocaine IV.

---

### Effect of ketorolac in intra-articular injection analgesia for postoperative pain in patients undergoing shoulder arthroscopy: a pilot-controlled clinical study [^1136miDk]. Journal of Pain Research (2019). Medium credibility.

Introduction

Shoulder arthroscopy is a common practice in managing shoulder diseases (such as rotator cuff tear, subacromial bursitis, and glenoid labial tear). About 45% of patients have severe pain postoperatively, which results in undue discomfort and delayed discharge.

There are many different analgesia methods (including intramuscular injections, intravenous injections, nerve blocks, and intra-articular analgesia) used in controlling pain. The optimal postoperative analgesia method for shoulder arthroscopy is still debated. In the last decade, a regional approach (intraoperative infiltration and intra-articular injection) using local anesthetics has become a popular analgesic method for shoulder arthroscopy. Stein et al reported the effectiveness and safety of intra-articular morphine after arthroscopic knee surgery, which is explained by the presence of opiate receptors in the nerve endings anchored to the inflamed synovial tissue. Levine and Taiwo confirmed the same result and reported that morphine had a mild but definite analgesic effect via a binding site with the characteristics of the mu-opioid receptor. Compared with hyaluronic acid and saline, triamcinolone acetonide produced a faster reduction in pain after injection. Panigrahi et al studied the analgesic effect of dexamethasone with ropivacaine, and confirmed that the combined intra-articular group had significantly low pain scores. Therefore, a multimodal drug regime (ropivacaine, morphine, and triamcinolone acetonide) is regularly used after shoulder arthroscopy in our clinics.

To the best of our knowledge, there has been little research concerning the use of nonsteroidal antiinflammatory drugs (NSAIDs) in the intra-articular injection mixture. We hypothesized that adding an intra-articular ketorolac injection would produce more profound pain relief, which could alter the sensitivity of the peripheral nociceptors activated by the trauma of surgery. The primary aim of this study was to evaluate the effect of using ketorolac in combination with a multimodal drug regime (ropivacaine, morphine, and tri-amcinolone acetonide) after shoulder arthroscopy. Morphine consumption and initial analgesic desired time were measured as secondary end points. Finally, we investigated the safety of an intra-articular ketorolac injection.

---

### Prednisolone and ketorolac vs ketorolac monotherapy or sub-tenon prophylaxis for macular thickening in cataract surgery: a randomized clinical trial [^114DBKhD]. JAMA Ophthalmology (2021). High credibility.

Importance

The choice of anti-inflammatory prophylaxis parallel to cataract surgery is important for patient safety and successful outcome of surgery, but which regimen to choose is contested.

Objectives

To determine whether a combination of prednisolone and nonsteroidal anti-inflammatory drug (NSAID) eye drops was superior in preventing increased central macular thickness (central subfield thickness [CST]) after uncomplicated cataract surgery compared with NSAID monotherapy and sub-Tenon capsule depot (dropless surgery), and to test whether preoperative initiation of eye drop treatment was superior to initiation on the day of surgery.

Design, Setting, and Participants

This investigator-driven, single-center, randomized clinical trial with masked statistical analyses enrolled patients at the Department of Ophthalmology, Rigshospitalet Glostrup, Glostrup, Denmark, from February 1, 2018, to August 15, 2019. Follow-up was completed December 18, 2019. Participants included low-risk patients undergoing phacoemulsification for age-related cataract by an experienced surgeon (1 eye per participant). Data were analyzed from February 17 to June 15, 2020.

Interventions

Participants scheduled for cataract removal were randomized to 1 of 5 anti-inflammatory prophylactic regimens: eye drops with a combination of prednisolone, 1%, and ketorolac tromethamine, 0.5%, with or without preoperative initiation (preoperative prednisolone plus NSAID [control] and postoperative prednisolone plus NSAID groups), ketorolac monotherapy with or without preoperative initiation (preoperative and postoperative NSAID groups), or sub-Tenon depot of dexamethasone phosphate (sub-Tenon group). Eye drops were administered 3 times per day until 3 weeks postoperatively.

Main Outcomes and Measures

CST 3 months postoperatively.

Results

A total of 470 participants (mean [SD] age, 72.2 [7.0] years; 290 women [61.7%]) with 94 participants in each group were included in the analysis. Three months after surgery, the mean CST was 250.7 (95% CI, 247.6–253.7) μm in the preoperative prednisolone plus NSAID group, 250.7 (95% CI, 247.8–253.7) μm in the postoperative prednisolone plus NSAID group, 251.3 (95% CI, 248.2–254.4) μm in the preoperative NSAID group, 249.2 (95% CI, 246.2–252.3) μm in the postoperative NSAID group, and 255.2 (95% CI, 252.0–258.3) μm in the sub-Tenon group. There were no significant differences in CST or visual acuity compared with control and no differences between preoperative and postoperative groups, but 47 of 83 participants (56.6%) in the sub-Tenon group needed additional anti-inflammatory treatment.

Conclusions and Relevance

No differences in CST or visual acuity were detected between the combination of prednisolone and NSAID eye drops vs NSAID monotherapy or sub-Tenon dexamethasone depot, although more than one-half of patients in the sub-Tenon arm received additional anti-inflammatory treatment. Initiating prophylaxis 3 days preoperatively was not superior to initiation on the day of surgery. Monotherapy with NSAIDs may be preferred in uncomplicated cataract surgery.

Trial Registration

ClinicalTrials.gov Identifier: NCT03383328.

---

### Efficacy and safety of non-steroidal anti-inflammatory drugs (NSAIDs) for the treatment of acute pain after orthopedic trauma: a practice management guideline from the Eastern Association for the Surgery of Trauma and the orthopedic trauma association [^115JgWAL]. Trauma Surgery & Acute Care Open (2023). High credibility.

Regarding medical management for pelvic trauma, more specifically with respect to pain management, AOTA/EAST 2023 guidelines recommend to consider administering NSAIDs (such as ketorolac) for pain management in adult patients with a traumatic fracture.

---

### Ketorolac tromethamine (Acunivive 90) [^116KGuXT]. FDA (2022). Medium credibility.

Diuretics

Clinical studies, as well as postmarketing observations, have shown that ketorolac tromethamine can reduce the natriuretic effect of furosemide and thiazides in some patients. This response has been attributed to inhibition of renal prostaglandin synthesis. During concomitant therapy with NSAIDs, the patient should be observed closely for signs of renal failure (see WARNINGS, Renal Effects), as well as to assure diuretic efficacy.

Probenecid

Concomitant administration of oral ketorolac tromethamine and probenecid resulted in decreased clearance and volume of distribution of ketorolac and significant increases in ketorolac plasma levels (total AUC increased approximately threefold from 5.4 to 17.8 mcg/h/mL) and terminal half-life increased approximately twofold from 6.6 to 15.1 hours. Therefore, concomitant use of ketorolac tromethamine and probenecid is contraindicated.

Lithium

NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance. The mean minimum lithium concentration increased 15% and the renal clearance was decreased by approximately 20%. These effects have been attributed to inhibition of renal prostaglandin synthesis by the NSAID. Thus, when NSAIDs and lithium are administered concurrently, subjects should be observed carefully for signs of lithium toxicity.

Methotrexate

NSAIDs have been reported to competitively inhibit methotrexate accumulation in rabbit kidney slices. This may indicate that they could enhance the toxicity of methotrexate. Caution should be used when NSAIDs are administered concomitantly with methotrexate.

ACE Inhibitors/Angiotensin II Receptor Antagonists

Concomitant use of ACE inhibitors and/or angiotensin II receptor antagonists may increase the risk of renal impairment, particularly in volume-depleted patients.

Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE inhibitors and/or angiotensin II receptor antagonists. This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE inhibitors and/or angiotensin II receptor antagonists.

Antiepileptic Drugs

Sporadic cases of seizures have been reported during concomitant use of ketorolac tromethamine and antiepileptic drugs (phenytoin, carbamazepine).

Psychoactive Drugs

Hallucinations have been reported when ketorolac tromethamine was used in patients taking psychoactive drugs (fluoxetine, thiothixene, alprazolam).

Pentoxifylline

When ketorolac tromethamine is administered concurrently with pentoxifylline, there is an increased tendency to bleeding.

---

### Efficacy and safety of non-steroidal anti-inflammatory drugs (NSAIDs) for the treatment of acute pain after orthopedic trauma: a practice management guideline from the Eastern Association for the Surgery of Trauma and the orthopedic trauma association [^1172GdqZ]. Trauma Surgery & Acute Care Open (2023). High credibility.

Regarding medical management for distal radius fracture, more specifically with respect to pain management, AOTA/EAST 2023 guidelines recommend to consider administering NSAIDs (such as ketorolac) for pain management in adult patients with a traumatic fracture.

---

### Prophylactic non-steroidal anti-inflammatory drugs for the prevention of macular oedema after cataract surgery [^117AwRKa]. The Cochrane Database of Systematic Reviews (2016). Low credibility.

Background

Macular oedema (MO) is the accumulation of extracellular fluid in the central retina (the macula). It may occur after cataract surgery and may give rise to poor visual outcome, with reduced visual acuity and distortion of the central vision. MO is often self-limiting with spontaneous resolution, but a small proportion of people with chronic persistent MO may be difficult to treat. Chronic oedema may lead to the formation of cystic spaces in the retina termed 'cystoid macular oedema' (CMO). Non-steroidal anti-inflammatory drugs (NSAIDs) are commonly used in cataract surgery and may reduce the chances of developing MO.

Objectives

The aim of this review is to answer the question: is there evidence to support the prophylactic use of topical NSAIDs either in addition to, or instead of, topical steroids postoperatively to reduce the incidence of macular oedema (MO) and associated visual morbidity.

Search Methods

We searched a number of electronic databases including CENTRAL, MEDLINE and Embase. Date last searched 2 September 2016.

Selection Criteria

We included randomised controlled trials (RCTs) in which adult participants had undergone surgery for age-related cataract. We included participants irrespective of their baseline risk of MO, in particular we included people with diabetes and uveitis. We included trials of preoperative and/or postoperative topical NSAIDs in conjunction with postoperative topical steroids. The comparator was postoperative topical steroids alone. A secondary comparison was preoperative and/or postoperative topical NSAIDs alone versus postoperative topical steroids alone.

Data Collection and Analysis

Two review authors independently selected studies for inclusion, assessed risk of bias and extracted data using standard methods expected by Cochrane. We pooled data using a random-effects model. We graded the certainty of the evidence using GRADE and considered the following: risk of bias of included studies, precision of the effect estimate, consistency of effects between studies, directness of the outcome measure and publication bias.

Main Results

We identified 34 studies that were conducted in the Americas, Europe, the Eastern Mediterranean region and South-East Asia. Over 5000 people were randomised in these trials. The majority of studies enrolled one eye per participant; a small subset (4 trials) enrolled a proportion of people with bilateral surgery. Twenty-eight studies compared NSAIDs plus steroids with steroids alone. Six studies compared NSAIDs with steroids. A variety of NSAIDs were used, including ketorolac, diclofenac, nepafenac, indomethacin, bromfenac, flurbiprofen and pranopfen. Follow-up ranged from one to 12 months. In general, the studies were poorly reported. We did not judge any of the studies at low risk of bias in all domains. Six studies were funded by industry, seven studies were funded from non-industry sources, and the rest of the studies did not report the source of funding. There was low-certainty evidence that people receiving topical NSAIDs in combination with steroids may have a lower risk of poor vision due to MO at three months after cataract surgery compared with people receiving steroids alone (risk ratio (RR) 0.41, 95% confidence interval (CI) 0.23 to 0.76; eyes = 1360; studies = 5; I² = 5%). We judged this to be low-certainty evidence because of risk of bias in the included studies and indirectness, as the extent of visual loss was not always clear. Only one study reported poor vision due to MO at 12 months and we judged this to be very low-certainty evidence as there were only two events. Quality of life was only reported in one of the 34 studies comparing NSAIDs plus steroids versus steroids alone, and it was not fully reported, other than to comment on lack of differences between groups. There was evidence of a reduced risk of MO with NSAIDs at three months after surgery, but we judged this to be low-certainty due to risk of bias and publication bias (RR 0.40, 95% CI 0.32 to 0.49; eyes = 3638; studies = 21). There was inconsistent evidence on central retinal thickness at three months (I 2 = 87%). Results ranged from -30.9 µm in favour of NSAIDs plus steroids to 7.44 µm in favour of steroids alone. Similarly, data on best corrected visual acuity (BCVA) were inconsistent, but nine out of 10 trials reporting this outcome found between-group differences in visual acuity of less than 0.1 logMAR. None of the six studies comparing NSAIDs alone with steroids reported on poor vision due to MO at three or 12 months. There was low-certainty evidence that central retinal thickness was lower in the NSAIDs group at three months (mean difference (MD) -22.64 µm, 95% CI -38.86 to -6.43; eyes = 121; studies = 2). Five studies reported on MO and showed a reduced risk with NSAIDs, but we judged this evidence to be of low-certainty (RR 0.27, 95% CI 0.18 to 0.41; eyes = 520). Three studies reported BCVA at three months and the results of these trials were inconsistent, but all three studies found differences of less than 0.1 logMAR between groups. We did not note any major adverse events - the main consistent observation was burning or stinging sensation with the use of NSAIDs.

Authors' Conclusions

Using topical NSAIDs may reduce the risk of developing macular oedema after cataract surgery, although it is possible that current estimates as to the size of this reduction are exaggerated. It is unclear the extent to which this reduction has an impact on the visual function and quality of life of patients. There is little evidence to suggest any important effect on vision after surgery. The value of adding topical NSAIDs to steroids, or using them as an alternative to topical steroids, with a view to reducing the risk of poor visual outcome after cataract surgery is therefore uncertain. Future trials should address the remaining clinical uncertainty of whether prophylactic topical NSAIDs are of benefit, particularly with respect to longer-term follow-up (at least to 12 months), and should be large enough to detect reduction in the risk of the outcome of most interest to patients, which is chronic macular oedema leading to visual loss.

---

### Safety of ketorolac in surgical neonates and infants 0 to 3 months old [^116Btr36]. Journal of Pediatric Surgery (2011). Low credibility.

Background

Ketorolac is a nonsteroidal antiinflammatory drug widely used as an adjunct to postoperative pain control in adult and pediatric patients. Minimal safety data exist regarding the use of ketorolac in neonates.

Methods

The charts of 57 postsurgical neonates between 0 and 3 months of age were retrospectively reviewed for bleeding events associated with ketorolac. Data included gestational age (GA), corrected gestational age (CGA) at the time of ketorolac, serum creatinine, platelet count, urine output (in milliliters per kilogram per hour), concomitant medications, enteral feeds, number of ketorolac doses, and surgical procedure performed.

Results

Of 57 patients, 10 (17.2%) demonstrated a bleeding event. Mean CGA and serum creatinine for those with bleeding events was 39.4 weeks (P = 0.69) and 0.64 mg/dL (P = 0.03), respectively. Patients with a bleeding event received ketorolac at a mean of 20.7 days of life with 70% receiving the drug at less than 14 days of age, whereas those without a bleeding event received ketorolac at a mean of 31.9 days (P = 0.04). Bleeding events correlated with glomerular filtration rate of less than 30 mL/min/1.73 m² or concomitant medications in all but 1 patient.

Conclusions

Infants younger than 21 days and less than 37 weeks CGA are at significantly increased risk for bleeding events and should not be candidates for ketorolac therapy.

---

### The impact of prophylactic dexamethasone on postoperative sore throat: an updated systematic review and meta-analysis [^112vTh5v]. Journal of Pain Research (2018). Low credibility.

Results

Trial identification

A total of 645 articles were identified by comprehensive search. Fourteen RCTs were finally included for meta-analysis after screening of titles, abstracts, or full text articles (Figure 1).

Characteristics of included studies

The characteristics of the studies included are shown in Table 1. Fourteen RCTs totaling 1,837 patients undergoing general anesthesia with tracheal intubation were included.

Patients classified as ASA class I or II were included in majority of the RCTs. Exclusion criteria were as follows: pregnancy, diabetes mellitus, obesity, and any contraindication to corticosteroid medications. Dexamethasone ranging from 4 to 0.2 mg/kg was administered intravenously in single or combination except one RCTadministered locally. Timing of dexamethasone administration varied from 30 minutes before tracheal intubation to 30 minutes after tracheal intubation. Controls included placebo, ondansetron, magnesium sulfate, ketamine gargle, betamethasone gel, and ketorolacor a combination of these medications. Regarding the methodological quality of the RCTs, all showed low overall risks of bias (Table 2).

Treatment effects

---

### Methylprednisolone (methylprednisolone sodium succinate) [^111JGbdd]. FDA (2024). Medium credibility.

Labeled indications for Methylprednisolone sodium succinate (also known as Solu-Medrol) include:

- Treatment of dermatomyositis and polymyositis in adults
- Treatment of contact dermatitis in adults
- Treatment of Stevens-Johnson syndrome in adults
- Treatment of idiopathic thrombocytopenic purpura in adults
- Treatment of autoimmune hemolytic anemia in adults (acquired)
- Treatment of erythroblastopenia in adults

---

### Best practices guidelines for acute pain management in trauma patients [^114sUmrq]. ACS (2020). High credibility.

Table 10 — Ward multimodal pain management lists nonpharmacologic strategies (positioning, splinting, heat/cold, calming); APAP/NSAIDs unless contraindicated; symptom-driven adjuvant therapy (e.g., antiepileptics, SMRs, SNRIs); oral opioids (oxycodone, tramadol); short-acting IV for procedural/severe pain (e.g., ketamine, opioids, ketorolac); alpha-2 agonists (clonidine); local anesthetic (for painful local procedures); and regional blocks.

---

### Practice guidelines for acute pain management in the perioperative setting: an updated report by the American society of anesthesiologists task force on acute pain management [^115tNVKP]. Anesthesiology (2012). Medium credibility.

Multimodal techniques with systemic analgesics — intravenous morphine combined with ketorolac improves pain scores and reduces analgesic use (Category A1 evidence) compared with intravenous morphine, with equivocal findings for nausea and vomiting (Category C1 evidence); combining intravenous morphine with ketamine yields equivocal findings (Category C1 evidence); combining intravenous patient-controlled opioid analgesia with oral cyclooxygenase-2 selective or nonselective NSAIDs shows inconsistent findings, and acetaminophen findings are equivocal (Category C2 evidence); and combining intravenous opioids with calcium channel blockers (gabapentin, pregabalin) lowers pain scores and reduces opioid use (Category A1 evidence) without differences in nausea or vomiting (Category C1 evidence).

---

### Post-operative pain management modalities employed in clinical trials for adult patients in LMIC; a systematic review [^114Roy5S]. BMC Anesthesiology (2021). Medium credibility.

Multimodal analgesia is recommended for postoperative pain relief following total abdominal hysterectomy (TAH). For severe pain, PROSPECT recommends strong opioids using PCA along with NSAIDs such as Diclofenac. Opioids can be administered as a continuous infusion, when PCA is not feasible. Weak opioids can be substituted along with paracetamol and NSAIDs when pain decreases to moderate intensity. Though epidural analgesia is not recommended for routine use, it is considered useful for high-risk patients undergoing TAH. In both the RCTs conducted in LMIC on post-hysterectomy pain, multimodal analgesia was not employed, rather pre-emptive analgesic effect of gabapentin (plus dexamethasone) or pregabalin was studied on consumption of a single postoperative analgesic agent (ketorolac or pethidine. Both used placebo for usual care groups.

A multimodal approach has been recommended for perioperative pain management in major breast cancer surgery. A successful multimodal approach requires coordination between surgical, anaesthesia, and nursing staff throughout perioperative period. Recent recommendations are to use antiepileptic medication or gabapentinoids (gabapentin or pregabalin), paracetamol, and regional nerve blocks (paravertebral blocks, PEC blocks, or thoracic epidural injection), wound infiltration with LA at the end, NSAIDs, and intermittent short-acting opioids. This regimen should be continued for up to 1 week after surgery. Other classes of medications can also be used such as, intravenous lignocaine, N-methyl-D-aspartate (NMDA) antagonists such as ketamine and magnesium, alpha-2-adrenergic antagonists clonidine and dexmedetomidine. Glucocorticoids such as dexamethasone have been used to minimize postoperative pain, nausea and vomiting.

---

### Single-dose intravenous ketorolac for acute postoperative pain in adults [^113ZZX4Q]. The Cochrane Database of Systematic Reviews (2021). Medium credibility.

Background

Postoperative pain is common and may be severe. Postoperative administration of non-steroidal anti-inflammatory drugs (NSAIDs) reduces patient opioid requirements and, in turn, may reduce the incidence and severity of opioid-induced adverse events (AEs).

Objectives

To assess the analgesic efficacy and adverse effects of single-dose intravenous ketorolac, compared with placebo or an active comparator, for moderate to severe postoperative pain in adults.

Search Methods

We searched the following databases without language restrictions: CENTRAL, MEDLINE, Embase and LILACS on 20 April 2020. We checked clinical trials registers and reference lists of retrieved articles for additional studies.

Selection Criteria

Randomized double-blind trials that compared a single postoperative dose of intravenous ketorolac with placebo or another active treatment, for treating acute postoperative pain in adults following any surgery.

Data Collection and Analysis

We used standard methodological procedures expected by Cochrane. Our primary outcome was the number of participants in each arm achieving at least 50% pain relief over a four- and six-hour period. Our secondary outcomes were time to and number of participants using rescue medication; withdrawals due to lack of efficacy, adverse events (AEs), and for any other cause; and number of participants experiencing any AE, serious AEs (SAEs), and NSAID-related or opioid-related AEs. For subgroup analysis, we planned to analyze different doses of parenteral ketorolac separately and to analyze results based on the type of surgery performed. We assessed the certainty of evidence using GRADE.

Main Results

We included 12 studies, involving 1905 participants undergoing various surgeries (pelvic/abdominal, dental, and orthopedic), with 17 to 83 participants receiving intravenous ketorolac in each study. Mean study population ages ranged from 22.5 years to 67.4 years. Most studies administered a dose of ketorolac of 30 mg; one study assessed 15 mg, and another administered 60 mg. Most studies had an unclear risk of bias for some domains, particularly allocation concealment and blinding, and a high risk of bias due to small sample size. The overall certainty of evidence for each outcome ranged from very low to moderate. Reasons for downgrading certainty included serious study limitations, inconsistency and imprecision. Ketorolac versus placebo Very low-certainty evidence from eight studies (658 participants) suggests that ketorolac results in a large increase in the number of participants achieving at least 50% pain relief over four hours compared to placebo, but the evidence is very uncertain (risk ratio (RR) 2.81, 95% confidence interval (CI) 1.80 to 4.37). The number needed to treat for one additional participant to benefit (NNTB) was 2.4 (95% CI 1.8 to 3.7). Low-certainty evidence from 10 studies (914 participants) demonstrates that ketorolac may result in a large increase in the number of participants achieving at least 50% pain relief over six hours compared to placebo (RR 3.26, 95% CI 1.93 to 5.51). The NNTB was 2.5 (95% CI 1.9 to 3.7). Among secondary outcomes, for time to rescue medication, moderate-certainty evidence comparing intravenous ketorolac versus placebo demonstrated a mean median of 271 minutes for ketorolac versus 104 minutes for placebo (6 studies, 633 participants). For the number of participants using rescue medication, very low-certainty evidence from five studies (417 participants) compared ketorolac with placebo. The RR was 0.60 (95% CI 0.36 to 1.00), that is, it did not demonstrate a difference between groups. Ketorolac probably results in a slight increase in total adverse event rates compared with placebo (74% versus 65%; 8 studies, 810 participants; RR 1.09, 95% CI 1.00 to 1.19; number needed to treat for an additional harmful event (NNTH) 16.7, 95% CI 8.3 to infinite, moderate-certainty evidence). Serious AEs were rare. Low-certainty evidence from eight studies (703 participants) did not demonstrate a difference in rates between ketorolac and placebo (RR 0.62, 95% CI 0.13 to 3.03). Ketorolac versus NSAIDs Ketorolac was compared to parecoxib in four studies and diclofenac in two studies. For our primary outcome, over both four and six hours there was no evidence of a difference between intravenous ketorolac and another NSAID (low-certainty and moderate-certainty evidence, respectively). Over four hours, four studies (337 participants) produced an RR of 1.04 (95% CI 0.89 to 1.21) and over six hours, six studies (603 participants) produced an RR of 1.06 (95% CI 0.95 to 1.19). For time to rescue medication, low-certainty evidence from four studies (427 participants) suggested that participants receiving ketorolac waited an extra 35 minutes (mean median 331 minutes versus 296 minutes). For the number of participants using rescue medication, very low-certainty evidence from three studies (260 participants) compared ketorolac with another NSAID. The RR was 0.90 (95% CI 0.58 to 1.40), that is, there may be little or no difference between groups. Ketorolac probably results in a slight increase in total adverse event rates compared with another NSAID (76% versus 68%, 5 studies, 516 participants; RR 1.11, 95% CI 1.00 to 1.23; NNTH 12.5, 95% CI 6.7 to infinite, moderate-certainty evidence). Serious AEs were rare. Low-certainty evidence from five studies (530 participants) did not demonstrate a difference in rates between ketorolac and another NSAID (RR 3.18, 95% CI 0.13 to 76.99). Only one of the five studies reported a single serious AE.

Authors' Conclusions

The amount and certainty of evidence for the use of intravenous ketorolac as a treatment for postoperative pain varies across efficacy and safety outcomes and amongst comparators, from very low to moderate. The available evidence indicates that postoperative intravenous ketorolac administration may offer substantial pain relief for most patients, but further research may impact this estimate. Adverse events appear to occur at a slightly higher rate in comparison to placebo and to other NSAIDs. Insufficient information is available to assess whether intravenous ketorolac has a different rate of gastrointestinal or surgical-site bleeding, renal dysfunction, or cardiovascular events versus other NSAIDs. There was a lack of studies in cardiovascular surgeries and in elderly populations who may be at increased risk for adverse events.

---

### A novel treatment of central serous chorioretinopathy with topical anti-inflammatory therapy [^113PviE6]. BMJ Case Reports (2012). Medium credibility.

A 45-year-old Caucasian female with diagnosis of central serous chorioretinopathy (CSCR) did not improve on conventional observational approach. She was not willing to proceed with photocoagulation or photodynamic therapy. An unconventional approach of topical anti-inflammatory (ketorolac, dexamethasone and hydrocortisone) preparation was prescribed. The course of her CSCR responded well on this unconventional treatment, but relapsed on cessation or tapering of treatment. After 18 weeks of treatment with a gradual taper, her condition resolved. The present case highlights an alternative but unconventional treatment of CSCR with prolonged use of anti-inflammatories.

---

### Comparison of morphine, ketorolac, and their combination for postoperative pain: results from a large, randomized, double-blind trial [^1158RtRQ]. Anesthesiology (2005). Low credibility.

Background

Meta-analyses report similar numbers needed to treat for nonsteroidal antiinflammatory drugs (NSAIDs) and opioids. Differences in baseline pain intensity among the studies from which these numbers needed to treat were derived may have confounded the results. NSAIDs have an opioid-sparing effect, but the importance of this effect is unclear. Therefore, the authors sought to compare the proportions of subjects who obtain pain relief with ketorolac versus morphine after surgery and to determine whether the opioid-sparing effect of an NSAID reduces the magnitude of opioid side effects.

Methods

The study was a double-blind, randomized controlled trial. The authors randomly assigned 1,003 adult patients to receive 30 mg ketorolac or 0.1 mg/kg morphine intravenously. They calculated the proportion of subjects who achieved at least 50% reduction in pain intensity 30 min after analgesic administration. Further, so long as pain intensity 30 min after analgesic administration was 5 or more out of 10, patients received 2.5 mg morphine every 10 min until pain intensity was 4 or less out of 10. The authors assessed the presence of opioid-related side effects.

Results

Five hundred patients received morphine and 503 received ketorolac. Fifty percent of patients in the morphine group achieved pain relief, compared with 31% in the ketorolac group (difference, 19%; 95% confidence interval, 13–25%). The ketorolac-morphine group required less morphine (difference, 6.5 mg; 95% confidence interval, -5.8 to -7.2) and had a lower incidence of side effects (difference, 11%; 95% confidence interval, 5–16%) than the morphine group.

Conclusions

Opioids are more efficacious analgesics than NSAIDs, although historic data for these two drugs yield similar numbers needed to treat. Adding NSAIDs to the opioid treatment reduces morphine requirements and opioid-related side effects in the early postoperative period.

---

### Efficacy and safety of non-steroidal anti-inflammatory drugs (NSAIDs) for the treatment of acute pain after orthopedic trauma: a practice management guideline from the Eastern Association for the Surgery of Trauma and the orthopedic trauma association [^114swZEV]. Trauma Surgery & Acute Care Open (2023). Medium credibility.

PICO 2

Should ketorolac be used in analgesic regimens for adult patients (≥ 18 years old) with traumatic fracture versus routine analgesic regimens that do not include ketorolac to improve analgesia and reduce OMEs, without increasing non-union rates?

Qualitative synthesis

Three studies compared ketorolac use to no ketorolac use in patients with traumatic fractures (table 5). McDonald et al randomized 128 patients undergoing fixation or ankle fractures to receive 30 mg intravenous ketorolac intraoperatively and 20 tablets of 10 mg ketorolac postoperatively. Additionally, both groups were prescribed 81 mg of ASA for deep vein thrombosis prevention. Opioid consumption was lower in patients randomized to receive ketorolac (21 OMEs compared with 29 OMEs, p = 0.04). Like the reduction in OMEs, pain scores were lower on postoperative days 1 to 3 in the patients receiving ketorolac. Finally, there was no difference in the proportion of patients with complete union (83% in ketorolac group compared with 77% in control group) at 12 weeks.

Table 5
PICO 2 – summary of all outcomes

Xu et al randomized 63 patients to receive a post-operative pump containing ketorolac+sufentanil or sufentanil alone. There was no significant difference in pain at 48 hours but significantly less sufentanil was used in the group randomized to receive ketorolac.

Eftekharian et al randomized patients with mandible fractures to receive a single dose of 30 mg ketorolac or placebo in the postanesthesia unit at the onset of pain. There was a significant reduction in analgesic requirements but no difference in pain intensity at any time points.

Quantitative synthesis

Quantitative synthesis was not possible for any of the outcomes due to either a lack of two or more studies and inconsistent outcome definitions with respect to the timing of pain and methods to measure pain.

PICO 2 recommendation

We conditionally recommend ketorolac be used in analgesic regimens for adult patients (≥ 18 years old) with traumatic fracture. Ketorolac is associated with reduced opioid use and improved postoperative analgesia and is not associated with non-union. Five authors voted for a strong recommendation and 14 authors voted for conditional recommendation.

---

### Pain management for nonsyndromic craniosynostosis: adequate analgesia in a pediatric cohort? [^114hZKVZ]. The Journal of Craniofacial Surgery (2018). Low credibility.

Background

Postoperative pain following open craniosynostosis repair has not been studied extensively and is sometimes thought to be inconsequential. The purpose of this study was to assess postoperative pain in this pediatric population.

Methods

We performed a retrospective chart review of patients (n = 54) undergoing primary open craniosynostosis repair from 2010 to 2016. Demographics, length of stay (LOS), pain scores, emesis events, and perioperative analgesics were reviewed. Multivariable regression models were designed to assess for independent predictors of LOS and emesis.

Results

A high proportion had moderate to severe pain on postoperative day 0 (56.5%) and day 1 (60.9%). Opioid administered in postoperative period was 1.40mg/kg/d in morphine milligram equivalent (MME) (± 1.07mg/kg/d MME). Majority of patients transitioned to enteral opioids on postoperative day 1 (24.5%) or day 2 (49.1%). Ketorolac was administered to 11.1% (n = 6). Emesis was documented in 50% of patients. LOS revealed a positive association with age (P = 0.006), weight (P = 0.009), and day of transition to enteral opioids (P < 0.001); association with emesis was trending toward significance (P = 0.054). There was no association between overall LOS and amount of opioids administered postoperatively (P = 0.68). Postoperative emesis did not have any significant association with age, sex, weight, total amount of postoperative opioid administered, use of ketorolac, or intraoperative steroid use.

Conclusion

Open craniosynostosis repair is associated with high levels of pain and low utilization of nonopioid analgesics. Strategies to improve pain, decrease emesis and LOS include implementation of multimodal analgesia period and avoidance of enteral medications in the first 24hours after surgery.

---

### Methylprednisolone acetate [^116Mfs4N]. FDA (2025). Medium credibility.

The drug Methylprednisolone acetate.

---

### Perioperative single dose ketorolac to prevent postoperative pain: a meta-analysis of randomized trials [^114RbtL3]. Anesthesia and Analgesia (2012). Low credibility.

Background

Preventive analgesia using non-opioid analgesic strategies is recognized as a pathway to improve postoperative pain control while minimizing opioid-related side effects. Ketorolac is a nonsteroidal antiinflammatory drug frequently used to treat postoperative pain. However, the optimal dose and route of administration for systemic single dose ketorolac to prevent postoperative pain is not well defined. We performed a quantitative systematic review to evaluate the efficacy of a single dose of perioperative ketorolac on postoperative analgesia.

Methods

We followed the PRISMA statement guidelines. A wide search was performed to identify randomized controlled trials that evaluated the effects of a single dose of systemic ketorolac on postoperative pain and opioid consumption. Meta-analysis was performed using a random-effects model. Effects of ketorolac dose were evaluated by pooling studies into 30- and 60-mg dosage groups. Asymmetry of funnel plots was examined using Egger regression. The presence of heterogeneity was assessed by subgroup analysis according to the route of systemic administration (IV versus IM) and the time of drug administration (preincision versus postincision).

Results

Thirteen randomized clinical trials with 782 subjects were included. The weighted mean difference (95% confidence interval [CI]) of combined effects showed a difference for ketorolac over placebo for early pain at rest of -0.64 (-1.11 to -0.18) but not at late pain at rest, -0.29 (-0.88 to 0.29) summary point (0–10 scale). Opioid consumption was decreased by the 60-mg dose, with a mean (95% CI) IV morphine equivalent consumption of -1.64 mg (-2.90 to -0.37 mg). The opioid-sparing effects of ketorolac compared with placebo were greater when the drug was administered IM compared with when the drug was administered IV, with a mean difference (95% CI) IV morphine equivalent consumption of -2.13 mg (-4.1 to -0.21 mg). Postoperative nausea and vomiting were reduced by the 60-mg dose, with an odds ratio (95% CI) of 0.49 (0.29–0.81).

Conclusions

Single dose systemic ketorolac is an effective adjunct in multimodal regimens to reduce postoperative pain. Improved postoperative analgesia achieved with ketorolac was also accompanied by a reduction in postoperative nausea and vomiting. The 60-mg dose offers significant benefits but there is a lack of current evidence that the 30-mg dose offers significant benefits on postoperative pain outcomes.

---

### The effect of ketorolac tromethamine, methylprednisolone, and platelet-rich plasma on human chondrocyte and tenocyte viability [^113JogpG]. Arthroscopy (2013). Low credibility.

Purpose

The purpose of this study was to evaluate the effect on cell viability of the isolated and combined use of allogeneic platelet-rich plasma (PRP) and ketorolac tromethamine on human chondrocytes and tenocytes in a highly controlled in vitro environment.

Methods

PRP was produced from 8 subjects. Human chondrocytes (Lonza, Hopkinton, MA) and tenocytes isolated from samples of the long head of the biceps tendons were treated in culture with PRP, ketorolac tromethamine, and methylprednisolone, both alone and in combination. Control samples were treated in media containing 2% or 10% fetal bovine serum (FBS). Cells were exposed for 1 hour. Luminescence assays were obtained to examine cell viability after 24 hours and long-term effects on cell viability after 120 hours. Radioactive thymidine assay was used to measure proliferation after 120 hours.

Results

For chondrocytes, cell viability (120 hours) increased significantly with the treatment of PRP alone (43,949 ± 28,104 cells; P < .001) and with the combination of ketorolac tromethamine and PRP (43,276 ± 31,208; P < .001), compared with the 2% FBS group (7,397 ± 470). Cell viability decreased significantly after exposure to methylprednisolone (1,323 ± 776; P < .001) and its combination with PRP (4,381 ± 5,116; p < .001). For tenocytes, cell viability (120 hours) was significantly higher with the treatment of PRP (61,287 ± 23,273; P < .001) and the combined treatment of ketorolac tromethamine and PRP (52,025 ± 17,307; P < .001), compared with the 2% FBS group (23,042 ± 2,973). Cell viability decreased significantly after exposure to methylprednisolone (3,934 ± 1,791; p = 0.001) and its combination with PRP (5,201 ± 2,834; p = 0.003), compared with 2% FBS.

Conclusions

Tendon and cartilage cells showed increased cell viability after an exposure to allogeneic PRP and ketorolac tromethamine. Exposure to methylprednisolone alone decreased cell viability, and addition of PRP could partially reverse this negative effect.

Clinical Relevance

Intra-articular injections of pain-modifying or anti-inflammatory drugs are routinely given in orthopaedic practice. Among the many agents available for intra-articular injection, corticosteroids and local anesthetics are the most common in clinical practice. Potential detrimental side effects of intra-articular injections of corticosteroids and local anesthetics have prompted investigation into alternative treatment options such as combinations of PRP and ketorolac tromethamine. In vitro evaluation of their effect on cell viability might build a basis for further translational research and clinical application.

---

### Methylprednisolone (Medrol) [^115dUKfx]. FDA (2025). Medium credibility.

Regarding the use of methylprednisolone PO (also known as Medrol) in pregnant patients for all trimesters: use only if benefits outweigh potential risks. Evidence of fetal harm in animals. Infatns should be monitored for adrenal insufficiency. US FDA pregnancy category: C. There are no adequate or well-controlled studies on the use of methylprednisolone in pregnant women. Complications, including cleft palate, stillbirth, and premature abortion, have been reported when corticosteroids were administered during pregnancy in animals. If these drugs must be used during pregnancy, the potential risks should be discussed with the patient. The ACOG (ACOG) include methylprednisolone as a last-line treatment option for nausea and vomiting of pregnancy in patients who have failed other therapies and suggest a limited duration of use for this purpose in responding patients. The drug methylprednisolone PO (also known as Medrol) is classified under category A in the Australian categorisation system for prescribing medicines in pregnancy. This drug has been taken by a large number of pregnant women and women of childbearing age without any proven increase in the frequency of malformations or other direct or indirect harmful effects on the fetus having been observed.

---

### Best practices guidelines for acute pain management in trauma patients [^115oDHEL]. ACS (2020). High credibility.

Table 10 — Intensive Care Unit multimodal pain management includes nonpharmacologic strategies (e.g., positioning, splinting, heat/cold, calming); APAP (oral/IV); opioids (fentanyl, hydromorphone, morphine, oxycodone, tramadol); ketamine; alpha-2 agonists (clonidine, dexmedetomidine); NSAIDs unless contraindicated (e.g., ibuprofen, ketorolac IV, celecoxib); local anesthetic (for painful local procedures); regional blocks; and symptom-driven adjuvant therapy (e.g., antiepileptics, SMRs, SNRIs).

---

### Ketorolac in the perioperative management of acute type A aortic dissection: a randomized double-blind placebo-controlled trial [^111s8UTV]. BMC Medicine (2025). Medium credibility.

Discussion

In this randomized controlled trial, we observed no significant differences in adverse endpoints noted in existing guidelines or previous research between the ketorolac and placebo groups. Our findings suggest that short-term ketorolac administration, carefully monitored during the perioperative phase, is both safe and effective. Notably, it resulted in reduced intraoperative bleeding, shorter ICU stays, and potentially lower overall hospital costs, indicating its potential as a valuable option for aortic surgery patients.

We meticulously designed the study endpoints to balance clinical relevance and research significance. Drawing from animal studies, R-ketorolac has demonstrated the ability to reduce the incidence and severity of aTAAD, as well as modulate inflammatory biomarkers associated with the RAC1 pathway. Clinically, these findings correspond to improved treatment efficacy and patient prognosis. Previous studies have also linked ketorolac with a reduced incidence or trend toward mitigation of adverse endpoints, such as in-hospital mortality, permanent dialysis, tracheostomy, and neurological impairment. To align with these insights, we prioritized clinical adverse events as the primary endpoints and inflammation-related biomarkers as secondary endpoints. Safety, essential to trial feasibility, was designated as a primary observational endpoint, encompassing common adverse reactions and perioperative complications. Additionally, extensive perioperative data including vital signs, laboratory results, and imaging were included as secondary endpoints to ensure a comprehensive evaluation of ketorolac. Finally, composite endpoints were designed to integrate multiple adverse endpoints, providing a more comprehensive assessment of potential complications following aTAAD surgery. Compared to single indicators, composite endpoints offer a holistic reflection of complications' overall impact on patient prognosis, thus enabling a more thorough evaluation of ketorolac's effect on clinical outcomes.

---

### Intravenous ketorolac substantially reduces opioid use and length of stay after lumbar fusion: a randomized controlled trial [^117R2Nnm]. Spine (2024). Medium credibility.

Study Design

A randomized, double-blinded, placebo-controlled trial.

Objective

To examine the effect of intravenous ketorolac (IV-K) on hospital opioid use compared with IV-placebo (IV-P) and IV acetaminophen (IV-A).

Summary Of Background Data

Controlling postoperative pain while minimizing opioid use after lumbar spinal fusion is an important area of study.

Patients and Methods

Patients aged 18 to 75 years undergoing 1 to 2 level lumbar fusions between April 2016 and December 2019 were included. Patients with chronic opioid use, smokers, and those on systemic glucocorticoids or contraindications to study medications were excluded. A block randomization scheme was used, and study personnel, hospital staff, and subjects were blinded to the assignment. Patients were randomized postoperatively. The IV-K group received 15mg (age > 65) or 30mg (age < 65) every six hours (q6h) for 48 hours, IV-A received 1000 mg q6h, and IV-P received normal saline q6h for 48 hours. Demographic and surgical details, opioid use in morphine milliequivalents, opioid-related adverse events, and length of stay (LOS) were recorded. The primary outcome was in-hospital opioid use up to 72 hours.

Results

A total of 171 patients were included (58 IV-K, 55 IV-A, and 58 IV-P) in the intent-to-treat (ITT) analysis, with a mean age of 57.1 years. The IV-K group had lower opioid use at 72 hours (173 ± 157 mg) versus IV-A (255 ± 179 mg) and IV-P (299 ± 179 mg; P = 0.000). In terms of opiate use, IV-K was superior to IV-A (P = 0.025) and IV-P (P = 0.000) on ITT analysis, although on per-protocol analysis, the difference with IV-A did not reach significance (P = 0.063). When compared with IV-P, IV-K patients reported significantly lower worst (P = 0.004), best (P = 0.001), average (P = 0.001), and current pain (P = 0.002) on postoperative day 1, and significantly shorter LOS (P = 0.009) on ITT analysis. There were no differences in opioid-related adverse events, drain output, clinical outcomes, transfusion rates, or fusion rates.

Conclusions

By reducing opioid use, improving pain control on postoperative day 1, and decreasing LOS without increases in complications or pseudarthrosis, IV-K may be an important component of "enhanced recovery after surgery" protocols.

---

### Comparing the efficacy of combining ketorolac and paracetamol (acetaminophen) with paracetamol alone on postoperative pain after laminectomy. A double-blinded randomized clinical trial [^111tFE3S]. BMC Anesthesiology (2025). Medium credibility.

Conclusions

While both Paracetamol (Acetaminophen) and Ketorolac effectively manage postoperative pain, the combination of Paracetamol and Ketorolac offers the added benefit of reducing morphine requirements. According to this study, this was especially true during the early postoperative period. This opioid-sparing effect, along with better hemodynamic stability, outlines the clinical utility of this combination drug therapy approach in post-laminectomy pain management. Further research is warranted to explore the broader applicability of this approach in other surgical contexts.

---

### Effect of perioperative dexamethasone and different NSAIDs on anastomotic leak risk: a propensity score analysis [^116qYZST]. World Journal of Surgery (2016). Low credibility.

The main limitation of this study is its nonrandomized, retrospective nature. However, since the primary purpose of this study was to investigate the expected detrimental effects of NSAIDs on AL, and we unexpectedly discovered a nonsignificant protective effect of dexamethasone, an observer bias is not very likely. Ketorolac and dexamethasone were administered intravenously with a low risk of false registrations. In the electronically stored medication schedules, not only the ordinations were marked, but also whether they were received or not. However, possible confounding may occur if a patient does not take an oral dose of diclofenac delivered bedside. The main results of the study were not significant, most likely indicating a somewhat undersized study sample. In order to obtain significance based on the differences observed, a 2-fold increase in the number of patients would have been needed. Thus, in the no medication group, the number of patients would have to be increased from 117 to 188, in the diclofenac group from 59 to 187, and in the dexamethasone group from 66 to 108.

A strength of this study is that the electronically stored patient data were completely except from a single patient, and that virtually all patients operated on with intestinal anastomoses during the 3-year period could be retrieved from the data system. Due to the electronic health records and the universal health insurance coverage of all patients in Norway, we are certain to have captured most likely all patients with an AL. A patient with a late presentation of AL may in theory have been managed outside our health region, but the usual practice if such an event would occur is to receive a report from the managing hospital.

The use of NSAIDs for analgesia and dexamethasone to prevent nausea and vomiting was not part of a standard analgesic or antiemetic regimen but instead depended on the personal preferences of the anesthesiologist or surgeon on duty that day, and was therefore most probably randomly administered. Even so, there might have been some degree of selection bias with regard to contraindications against steroids and NSAIDs, such as peptic ulcer disease, asthma, heart, liver, or renal failure. We did not register detailed information about comorbidity in this study, but we did adjust for ASA score, which is a physical status classification system for assessing the fitness of the patient before surgery. The severity of systemic diseases is reflected in this score, and therefore, the use of it as a variable in the propensity score analysis will reduce the selection bias with regard to medicament contraindications among patients with comorbidities.

---

### Tramadol hydrochloride and acetaminophen (Ultracet) [^117Nka4m]. FDA (2012). Low credibility.

INDICATIONS AND USAGE

ULTRACET®is indicated for the short-term (five days or less) management of acute pain.

---

### Ketorolac tromethamine (Ketorolac) [^111AHnuq]. FDA (2011). Low credibility.

CLINICAL PHARMACOLOGY

Ketorolac tromethamine is a non-steroidal anti-inflammatory drug
(NSAID) that exhibits analgesic activity in animal models. The mechanism of
action of ketorolac, like that of other NSAIDs, is not completely understood but
may be related to prostaglandin synthetase inhibition. The biological activity
of ketorolac tromethamine is associated with the S-form. Ketorolac tromethamine
possesses no sedative or anxiolytic properties.

The peak analgesic effect of ketorolac tromethamine occurs within 2 to 3
hours and is not statistically significantly different over the recommended
dosage range of ketorolac tromethamine. The greatest difference between large
and small doses of ketorolac tromethamine is in the duration of analgesia.

Ketorolac tromethamine is a racemic mixture of S- and
R-enantiomeric forms, with the S-form having analgesic activity.

Comparison of IV, IM and Oral Pharmacokinetics

The pharmacokinetics of ketorolac tromethamine, following IV, IM
and oral doses of ketorolac tromethamine tablets, are compared in Table 1. In adults, the
extent of bioavailability following administration of the oral and IM forms of
ketorolac tromethamine was equal to that following an IV bolus.

---

### Acetaminophen and codeine phosphate (Codrix) [^113NXCdR]. FDA (2008). Low credibility.

INDICATIONS AND USAGE

CODRIX™ is indicated for the relief of mild to moderately severe pain.

---

### Ketotolac tromethamine [^111ozRAm]. FDA (2012). Low credibility.

Methotrexate

NSAIDs have been reported to competitively inhibit methotrexate
accumulation in rabbit kidney slices. This may indicate that they could enhance
the toxicity of methotrexate. Caution should be used when NSAIDs are
administered concomitantly with methotrexate.

ACE Inhibitors/Angiotension II Receptor
Antagonists

Concomitant use of ACE
inhibitors and/or angiotension II receptor antagonists may
increase the risk of renal impairment, particularly in volume-depleted patients.

Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE
inhibitors and/or angiotension II receptor antagonists. This interaction should
be given consideration in patients taking NSAIDs concomitantly with ACE
inhibitors and/or angiotension II receptor antagonists.

Antiepileptic Drugs

Sporadic cases of seizures have been reported during concomitant
use of ketorolac tromethamine and antiepileptic drugs (phenytoin,
carbamazepine).

Psychoactive Drugs

Hallucinations have been reported when ketorolac tromethamine was
used in patients taking psychoactive drugs (fluoxetine, thiothixene, alprazolam).

Pentoxifylline

When ketorolac tromethamine is administered concurrently with
pentoxifylline, there is an increased tendency to bleeding.

Nondepolarizing Muscle Relaxants

In post-marketing experience there have been reports of a
possible interaction between ketorolac tromethamine IV/IM and nondepolarizing muscle relaxants that resulted in apnea. The concurrent use of ketorolac
tromethamine with muscle relaxants has not been formally studied.

---

### Ketorolac tromethamine (Ketorolac) [^115bEPbv]. FDA (2011). Low credibility.

CLINICAL STUDIES

In a postoperative study, where all patients received morphine by
a PCA device, patients treated with ketorolac tromethamine-IV as fixed
intermittent boluses (e.g., 30 mg initial dose followed by 15 mg q3h), required
significantly less morphine (26%) than the placebo group. Analgesia was
significantly superior, at various postdosing pain assessment times, in the
patients receiving ketorolac tromethamine-IV plus PCA morphine as compared to
patients receiving PCA-administered morphine alone.

There is no data available to support the use of ketorolac
tromethamine tablets in pediatric patients.

---

### Best practices guidelines for acute pain management in trauma patients [^111stx8T]. ACS (2020). High credibility.

Nonsteroidal anti-inflammatory drugs (NSAIDs) for acute traumatic pain are supported as effective and opioid-sparing, with multiple studies establishing NSAIDs as equally effective to opioids for acute traumatic pain in adults and children, and when used alone or in combination with opioids, NSAIDs can greatly decrease opioid requirements. NSAIDs carry notable risks of gastrointestinal bleeding, acute kidney injury, and cardiovascular events; most risks are associated with long-term use, and risks may vary by COX selectivity, even between drugs in the same class, and although the primary risk of NSAID therapy is gastrointestinal bleeding, all NSAIDs have antiplatelet activity contributing to an increased risk of bleeding at any site. Antiplatelet effects occur mainly through COX-1 inhibition; therefore, selective COX-2 NSAIDs (e.g., celecoxib) have decreased risk of inhibiting platelet aggregation, and while no high-quality evidence exists regarding the use of NSAIDs in the presence of traumatic brain injury (TBI) or intracranial hemorrhage, most practitioners avoid the use of both COX-1 and COX-2 inhibitors in this setting. Perioperatively, NSAIDs are sometimes held preoperatively depending upon type of case and surgeon preference, prophylactic use of preoperative ketorolac is contraindicated due to bleeding risk, and clinicians should weigh the risk and impact of bleeding against the benefit of analgesia on a case-by-case basis; use NSAIDs cautiously in patients after colorectal resection because limited evidence suggests an increased risk of anastomotic failure. In musculoskeletal and spine contexts, recent literature demonstrates that short-term, early NSAID use does not increase risk of fracture nonunion, and a similar dose and duration-dependent effect is seen in spinal fusion, with early short (less than 48 hours) administration not having a significant deleterious effect on bony fusion, but aiding in early mobilization and discharge; avoid longer term (2 weeks or longer) use of NSAIDs in the setting of fracture. Use of NSAIDs, particularly at scheduled intervals, may contribute to or complicate the differential diagnosis of acute kidney injury, which develops in at least 30% of patients in ICU settings, and NSAIDs require caution when used in coagulopathic patients or those otherwise at risk for stress-related mucosal bleeding.

---

### Perineural methylprednisolone depot formulation decreases opioid consumption after total knee arthroplasty [^111TSag9]. Journal of Pain Research (2022). Medium credibility.

Nonetheless, we demonstrated an effective regimen using perineural DEX/MPA for analgesia following TKA that significantly decreased postoperative opioid consumption as compared to perineural use of DEX alone. Our institutional experience can certainly be considered in centers when other long duration of opioid-sparing pain control modalities is not readily available for TKA due to practical limitations such as prohibitory cost of patented medication or staffing restriction limiting the use of continuous nerve block catheters. A randomized controlled trial with longer duration of follow-up will be beneficial to systemically validate the utility and assess the safety of DEX and MPA combination in peripheral nerve block in the perioperative arena.

---

### Methylprednisolone acetate [^113KHGFL]. FDA (2025). Medium credibility.

Labeled indications for Methylprednisolone acetate include:

- Adjunctive treatment for gouty arthritis in adults (acute)
- Adjunctive treatment for subacute bursitis in adults
- Adjunctive treatment for acute bursitis in adults (acute episode)
- Adjunctive treatment for acute tenosynovitis in adults (acute nonspecific tenosynovitis)
- Adjunctive treatment for medial epicondylitis in adults (acute episode)
- Symptomatic relief of osteoarthritis in adults (large joints)
- Symptomatic relief of osteoarthritis in adults (medium joints)
- Symptomatic relief of osteoarthritis in adults (small joints)

---

### The clinical utility of new combination phenylephrine / ketorolac injection in cataract surgery [^111fm5Xj]. Clinical Ophthalmology (2015). Low credibility.

Pain management in cataract surgery

Preoperative drops for cataract surgery can also include diclofenac 0.1% a NSAID. Trauma to ocular tissue during surgery activates phospholipase A2, the precursor for arachidonic acid metabolites. Arachidonic acid metabolites act as a substrate for the cyclo-oxygenase (COX) pathways leading to the production of PGs E and F in aqueous humour. The effects of endogenous PGs are postoperative inflammation, miosis during surgery, conjunctival hyperemia, and changes in intraocular pressure.

NSAIDs work by inhibiting the COX pathway and hence the biosynthesis of PGs.

They are used to manage ocular inflammation, pain, and cystoid macular edema secondary to cataract surgery. Miosis during cataract surgery is in part related to the increased production of PGs during cataract surgery. Hence, NSAIDs are effective in maintenance of intraoperative mydriasis by their ability to block PG synthesis.

NSAIDs and steroid drops are also used perioperatively and continued postoperatively for post op inflammation and pain control. Topical NSAIDs have the advantage of avoiding the undesirable effects of topical corticosteroids, such as steroid induced raised intraocular pressure, cataract formation, and increased infection risk due to decreased immunological response.

A prospective study to evaluate postoperative pain following cataract surgery reported 1/3 of patients had ocular pain during the first 4 postoperative hours and 1/4 of these patients reported moderate to severe pain. With surgical centers use of postoperative pain assessments to be measures of clinical outcomes, pain management remains a primary concern for surgeons. Intracameral lidocaine was found to relieve intraoperative discomfort caused by iris movement or manipulation. A low pain score was reported in patients following combined topical and intracameral anesthesia during cataract surgery.

---

### Co-administered low doses of ibuprofen and dexamethasone produce synergistic antinociceptive effects on neuropathic mechanical allodynia in rats [^113pbD8t]. Journal of Pain Research (2019). Medium credibility.

Introduction

It has been well known that neuropathic pain results from conditions that compromise or abolish nerve function, including nerve injury, multiple sclerosis, and diabetes, and remains among the most challenging pain-related disorders to manage. A common symptom of neuropathic pain is allodynia, in which previously non-noxious stimuli are perceived as noxious following nerve injury. However, traditional analgesics including anticonvulsants, opioids, and nonsteroidal anti-inflammatory drugs (NSAIDs) lack efficacy in treating such pain and/or carry unpleasant side effects. Thus, neuropathic pain is an intractable disease from which only 40–60% of affected patients achieve even partial relief.

NSAIDs are widely used for the symptomatic relief of all kinds of pain, but lack efficacy in treating neuropathic pain. Moreover, NSAIDs are associated with adverse side effects, including perforation and bleeding of the gastrointestinal tract, resulting from their inhibitory activity on gastrointestinal prostaglandin E2 synthesis. Nevertheless, the intrathecal administration of an NSAID, meloxicam was found to attenuate the thermal hyperalgesia and mechanical allodynia induced by spinal nerve ligation. Moreover, in rats, the intrathecal injection of ketorolac, a cyclooxygenase (COX)-1 inhibitor, or NS-398, a COX-2 inhibitor, attenuated the hyperalgesia and allodynia resulting from a chronic constriction injury of the sciatic nerveand partial sciatic nerve ligation. These findings suggest that although the COX pathways play an important role in the nociceptive processing of neuropathic pain, the efficacy of COX inhibitors in treating this type of pain has not been established.

Dexamethasone is used to treat a wide variety of inflammatory conditions because it is a synthetic glucocorticoid with anti-inflammatory activity and minimal mineralocorticoid effects. A previous study demonstrated that dexamethasone produced potent anti-inflammatory effects on carrageenan-induced inflammation. Additionally, dexamethasone has been used for the treatment of neuropathic pain conditions. Previous reports have indicated that a subcutaneous injection of dexamethasone or epidural injection of betamethasone attenuated mechanical allodynia in rats with spinal nerve ligation. However, the prolonged use of dexamethasone can also be associated with serious side effects, suggesting that it has limited application in treating neuropathic pain conditions.

In our present study, we investigated the synergistic antinociceptive effects of co-administered low doses of ibuprofen and dexamethasone in rats with inferior alveolar nerve injury. Although these drugs were found to be largely ineffective against the pain when administered alone, we confirmed their synergistic antinociceptive effects when given in combination at a low dose by examining the changes in c-fos expression in the trigeminal subnucleus caudalis.

---

### Wilderness Medical Society clinical practice guidelines on anaphylaxis [^112AQ3Pt]. Wilderness & Environmental Medicine (2022). High credibility.

Anaphylaxis adjunctive therapy — corticosteroids: Prednisone is listed "1–2 mg·kg⁻¹, up to 50–60 mg QD". Methylprednisolone is listed "1–2 mg·kg⁻¹, up to 40–60 PO/IM QD, 80–125 mg IV QD". Dexamethasone is listed "6–9 mg QD Peds: 0.3 mg·kg⁻¹ QD". Indications include "Secondary treatment; bronchospasm; asthmatic patient; possible prevention of biphasic reaction", with recommendation "1C".

---

### Hydrocortisone (Alacort) [^1161QkDv]. FDA (2023). Medium credibility.

INDICATIONS AND USAGE

Topical corticosteroids are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.

---

### Comparing the efficacy of combining ketorolac and paracetamol (acetaminophen) with paracetamol alone on postoperative pain after laminectomy. A double-blinded randomized clinical trial [^112ksZGQ]. BMC Anesthesiology (2025). Medium credibility.

By investigating the results of this manuscript and other similar studies mentioned, it can be concluded that using a multi-drug analgesic approach, especially the combination of paracetamol and ketorolac, for opioid sparing after surgery is appropriate. Furthermore, it can be applied in different surgeries, such as abdominal hysterectomy, or even in different age groups, like children and young adults, undergoing emergent appendectomy. The Guan, J. et al. study reports the potential advantages derived from a comparative analysis of trends associated with opioid reduction and pain alleviation by investigating ketorolac in lumbar spine surgery. Kamal, Y.M. et al. Comparative study substantiates the opioid-sparing advantages inherent in multimodal strategies, thereby reinforcing the theoretical foundation of this manuscript.

Clinically, the implications of these findings are substantial. Reducing opioid consumption not only minimizes the risk of side effects such as nausea but also addresses broader concerns related to opioid dependence and misuse. The results support the multimodal analgesic approach for postoperative pain as a means to improve patient outcomes in the postoperative setting. Importantly, our findings also point to the potential long-term benefits of this analgesic strategy, underscoring the need for further research and larger patient cohorts to validate these benefits.

---

### Corticosteroid plus NSAID vs NSAID monotherapy or sub-tenon prophylaxis for cataract surgery… [^114wPjrE]. JAMA Network (2021). Excellent credibility.

Preoperative prednisolone plus nonsteroidal anti-inflammatory drug indicates group receiving a combination of prednisolone, 1%, and ketorolac tromethamine, 0. 5%, eye drops 3 times per day until 3 weeks after surgery with initiation 3 days before surgery;. postoperative prednisolone plus NSAID, group receiving a combination of prednisolone, 1%, and ketorolac, 0. 5%, eye drops 3 times per day until 3 weeks after surgery with initiation on the day of surgery; preoperative NSAID, group receiving monotherapy with ketorolac., 0. 5%, eye drops 3 times per day until 3 weeks after surgery with initiation 3 days before surgery; postoperative NSAID, group receiving monotherapy with ketorolac,
0. 5%, eye drops 3 times per day until 3 weeks after surgery with initiation on the day of surgery; and sub-Tenon, group receiving sub-Tenon depot consisting of 0. 5 mL of dexamethasone phosphate, 4 mg/mL.

Importance The choice of anti-inflammatory prophylaxis parallel to cataract surgery is important for patient safety and successful outcome of surgery, but which regimen to choose is contested. Objectives To determine whether a combination of prednisolone and nonsteroidal anti-inflammatory drug eye drops was superior in preventing increased central macular thickness after uncomplicated cataract surgery compared with NSAID monotherapy and sub-Tenon capsule depot, and to test whether preoperative initiation of eye drop treatment was superior to initiation on the day of surgery. Interventions Participants scheduled for cataract removal were randomized to 1 of 5 anti-inflammatory prophylactic regimens: eye drops with a combination of prednisolone, 1%, and ketorolac tromethamine, 0.

5%, with or without preoperative initiation, ketorolac monotherapy with or without preoperative initiation, or sub-Tenon depot of dexamethasone phosphate. No differences in CST or visual acuity were detected between the combination of prednisolone and NSAID eye drops vs NSAID monotherapy or sub-Tenon dexamethasone depot, although more than one-half of patients in the sub-Tenon arm received additional anti-inflammatory treatment. Initiating prophylaxis 3 days preoperatively was not superior to initiation on the day of surgery. Monotherapy with NSAIDs may be preferred in uncomplicated cataract surgery. It is believed that PCME is caused by the inflammatory response after cataract surgery, which disrupts the blood-ocular barrier leading to leakage of fluid into the retina.

4 To control the inflammatory response and reduce the risk of PCME, prophylactic anti-inflammatory eye drops are prescribed parallel to cataract surgery. To our knowledge, no studies have compared a dropless approach with NSAID eye drops. The purpose of this study was to determine whether combination of prednisolone and NSAID eye drops is superior in preventing macular thickening after uncomplicated cataract surgery compared with NSAID monotherapy and dropless surgery using a sub–Tenon capsule dexamethasone phosphate depot and preoperative initiation of eye drop treatment is superior to initiating treatment on the day of surgery. Quiz Ref IDThis study was a randomized clinical trial comparing 5 different regimens for anti-inflammatory prophylaxis parallel to uncomplicated cataract surgery. The trial protocol and statistical analysis plan are found in Supplement 1 and Supplement 2, respectively.

---

### A different look at corticosteroids… [^1176iZBL]. AAFP (1998). Low credibility.

8 Most of the recognized use has previously been in hospitalized patients with acute laryngotracheo-bronchitis. The use of steroids in children with croup is associated with significant clinical improvement at about 12 hours post-treatment and results in less endotracheal intubation. 9 Most current research focuses on outpatient use of corticosteroids in the treatment of moderate and severe croup. Some authors have found that routine use of steroids reduces the need for hospitalization. Documented benefits of corticosteroid therapy in patients with PCP include reduced morbidity and mortality, decreased need for mechanical ventilation assistance and a reduced long-term decline in pulmonary function or exercise tolerance. 16 In addition, studies suggest that steroids may decrease the severity of toxic side effects, such as fever and rash associated with the use of trimethoprim-sulfamethoxazole, the primary anti-pneumocystis treatment.

15, 17 This benefit may enable the patient to complete the required course of antibiotic therapy. 14, 16, 19 The recommended dosing regimen is oral prednisone, 40 mg twice daily for five days, then 40 mg once daily for five days, then 20 mg daily for the duration of the anti-pneumocystis therapy. Methylprednisolone, given at 75 percent of the oral prednisone dosage, can be substituted if parenteral therapy is necessary. 14, 16, 19 This therapy should be initiated along with anti-pneumocystis treatment. A confirmatory diagnosis of PCP and HIV infection should be obtained, and other diseases, such as tuberculosis and cryptococcosis, should be ruled out before steroid therapy is begun. 14 Corticosteroids may mask the symptoms of these diseases once the immunosuppressive effect of therapy occurs.

Further investigation is required to determine the appropriate use and benefits of steroid therapy when the patient has concomitant life-threatening infections and when the patient has already received more than three days of anti-pneumocystis therapy and has developed significant hypoxia. 25 Thyroid storm is a life-threatening condition of the hyperthyroid state. 26 It most commonly occurs in patients with Graves' disease but may also occur in those with multinodular goiter or toxic adenoma. 27 It is treated by correcting the hyperthyroidism and treating the precipitating events. 26 Correction of the hyperthyroid state involves using drugs such as propylthiouracil or methimazole, beta blockers or corticosteroids, which decrease the peripheral effects of thyroid hormone and the conversion of thyroxine to the more potent triiodothyronine.

22, 26 Dexamethasone can be used for that purpose, at a dosage of 2 mg intravenously every six hours, and can eventually can be switched to an oral dosage of 2 mg every six hours.
28. Pain Management Corticosteroids are used as adjuvant analgesics for pain in cancer patients and patients with neuropathic pain such as herpes zoster–related neuropathy, spinal cord compression and pain following oral surgery. Prednisone, at a dosage of 7. 5 to 10 mg per day, may be useful in decreasing pain in some patients with advanced prostate cancer. 29 Higher dosages of prednisone have improved quality of life, decreased analgesic consumption and improved appetite in patients with preterminal cancer. 30 Dexamethasone was shown to be more effective than prednisone in patients with terminal cancer. Patients with nerve compression pain or pain resulting from increased intracranial pressure showed a better response when compared with patients with other pain syndromes.